Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Reference |
|---|
| "Malignant gliomas are difficult to treat systemically because of exclusion of many chemotherapeutic agents by the blood brain barrier." | ( Brem, H; Leong, KW; Tamargo, RJ, 1990) |
| "Malignant gliomas are the most common malignant brain tumors and are almost always fatal." | ( Coen, DM; Malick, A; Markert, JM; Martuza, RL; Ruffner, KL, 1991) |
| "Glioma are often histologically heterogenous." | ( Heindel, W; Heiss, WD; Herholz, K; Jeske, J, 1989) |
| "Rat C 6 glioma is known to possess a beta-adrenergic receptor with which intracellular cyclic adenosine monophosphate (cAMP) levels are altered to control cell growth in vitro." | ( Egawa, T; Hayakawa, T; Mogami, H; Sakamoto, Y; Shimizu, K; Ushio, Y; Yoshida, T, 1987) |
| "Human malignant gliomas are karyotypically heterogeneous, composed of many cellular populations and isolated cell types identifiable by cytogenetic techniques." | ( Shapiro, JR; Shapiro, WR, 1985) |
| "Malignant gliomas are known to exhibit hypermetabolic glucose consumption compared to normal brain." | ( Blacklock, JB; Di Chiro, G; Larson, SM; Oldfield, EH; Theodore, W; Tran, D; Wright, DC, 1987) |
| "Thus, the RG-2 glioma is not more "acidic" than adjacent brain tissue and its "alkaline" pHt probably reflects a large extracellular water content and plasma-like extracellular pH." | ( Arnold, JB; Junck, L; Rottenberg, DA, 1985) |
| "Chiasmatic optic glioma is a rare tumor with an erratic natural history, usually seen in young children." | ( Bilaniuk, L; Bruce, DA; Packer, RJ; Radcliffe, JL; Rosenstock, JG; Savino, P, 1985) |
| "Therapy of glioma is a function of numerous factors: their histology, localization and size, but also the age and functional state of the patient." | ( Cohadon, F; Loiseau, H; Pigneux, J; Rougier, A, 1984) |
| "Malignant gliomas are associated with a state of systemic immunosuppression which appears to be partially mediated by transforming growth factor beta (TGF-beta) secreted from glioma cells." | ( Kiefer, R; Streit, WJ; Supler, ML; Toyka, KV, 1994) |
| "Malignant gliomas are the most common malignant brain tumors and are almost universally fatal." | ( Coen, DM; Malick, A; Markert, JM; Martuza, RL, 1993) |
| "Brainstem gliomas are an important oncologic problem in the pediatric age group, constituting between 10 and 15% of childhood central nervous system neoplasms." | ( Friedman, HS; Kerby, T; Moghrabi, A; Tien, RD, 1995) |
| "Recurrent gliomas are most often treated by chemotherapy." | ( Liang, BC, 1996) |
| "Human malignant gliomas are rather resistant to all current therapeutic approaches including surgery, radiotherapy and chemotherapy as well as antibody-guided or cellular immunotherapy." | ( Fontana, A; Weller, M, 1995) |
| "Malignant human gliomas are characterized by an uncontrolled cell proliferation and infiltrative growth within the brain." | ( Bjerkvig, R; Cabrera, IG; Edvardsen, K; Engebraaten, O; Haugeland, HK; Lund-Johansen, M; Mahesparan, R; Tysnes, BB, 1997) |
| "Gliomas are regionally heterogeneous tumors." | ( Brotchi, J; Brucher, JM; Damhaut, P; Dethy, S; Goldman, S; Hildebrand, J; Levivier, M; Pirotte, B; Wikler, D, 1997) |
| "Malignant gliomas are highly resistant to chemotherapy, in part because of the blood-brain barrier, which restricts the delivery of chemotherapy to certain areas of tumor and their cellular heterogeneity, which leads to the selection and propagation of resistant clones." | ( Fueyo, J; Gomez-Manzano, C; Kyritsis, AP; Levin, VA; Martin-Duque, P; Perez-Soler, R; Puduvalli, VK; Yung, WK, 1998) |
| "Gliomas are primary brain tumors that arise from differentiated glial cells through a poorly understood malignant transformation." | ( Gillespie, Y; Khazaeli, MB; Sontheimer, H; Soroceanu, L, 1998) |
| "Gliomas are characterized by their extensive invasion into the brain parenchyma." | ( Bjerkvig, R; Haugland, HK; Tysnes, BB, 1997) |
| "Anaplastic gliomas are infiltrative tumors, and their ability to migrate through normal brain contributes to their highly malignant behavior." | ( Gillespie, GY; Gladson, CL; Manning, TJ; Rosenfeld, SS; Soroceanu, L, 1999) |
| "Pediatric brain gliomas are not always amenable for complete surgical excision, therefore adjuvant treatment for a large tumor mass is often required." | ( Alger, J; Gupta, RK; Lazareff, JA, 1999) |
| "Human malignant gliomas are highly invasive tumors." | ( Manning, TJ; Sontheimer, H; Soroceanu, L, 1999) |
| "Malignant gliomas are often treated with cisplatin (cis-diamminedichloroplatinum(II), CDDP) and radiation but results remain unsatisfactory." | ( Galla, HJ; Knüpfer, MM; Poppenborg, H; Preiss, R; Wolff, JE, 1999) |
| "Gliomas are highly invasive, invariably fatal intracerebral tumors." | ( Kaye, AH; Lepperdinger, G; Novak, U; Stylli, SS, 1999) |
| "Malignant gliomas are vascular or angiogenic tumors, which leads to the supposition that angiogenesis inhibition may represent a potentially promising strategy in the treatment of these tumors." | ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "This implies that gliomas are dependent upon dynamic HCO(-)(3)-independent H(+) buffering pathways such as the type 1 Na(+)/H(+) exchanger (NHE1)." | ( Cala, PM; Gorin, FA; Jorgensen, NK; McLean, LA; Roscoe, J, 2000) |
| "Malignant gliomas are frequent and the prognosis is poor." | ( Domula, M; Knüpfer, H; Knüpfer, MM; Van Gool, S; Wolff, JE, 2000) |
| "Malignant gliomas are the most common intracranial tumors and are considered incurable." | ( Barna, BP; Koga, S; Komata, T; Kondo, S; Kondo, Y; Mukai, S, 2000) |
| "Malignant gliomas are the most common primary brain tumors in adults and, with few exceptions, have a dismal prognosis despite the therapeutic use of surgery, radiation therapy, and chemotherapy." | ( Bateman, A; Diaz, RM; Galanis, E; James, CD; Johnson, K; Russell, SJ; Vile, R, 2001) |
| "Low-grade gliomas are uncommon primary brain tumors classified as histologic grades I or II in the World Health Organization (WHO) classification." | ( Stieber, VW, 2001) |
| "Gliomas are the most common primary intracerebral tumours and over 60% of these are malignant." | ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "Malignant gliomas are usually refractory to aggressive combined-modality therapy, and the incidence of recurrence and death after treatment is very high." | ( Dowsett, R; Hong, T; Kaufman, S; Pinkerton, A; Simon, R; Voynov, G, 2002) |
| "Gliomas are the most common types of brain tumors, which invariably lead to death over months or years." | ( Deckert, M; Dittmar, C; Garlip, G; Gossman, A; Graf, R; Heiss, WD; Herholz, K; Hilker, R; Jacobs, AH; Kracht, L; Kummer, C; Sobesky, J; Thiel, A; Voges, J; Vollmar, S; Wienhard, K; Winkler, A, 2002) |
| "As gliomas are highly multidrug resistant, it is expected that the tracers would be poorly retained in those cells, but the in vivo and in vitro studies to date have shown that Tfos was highly retained in malignant gliomas." | ( Denoyer, D; Dubois, F; Koumanov, F; Perek, N, 2002) |
| "Gliomas are invasive malignant tumours with poor prognosis." | ( Desaknai, S; Esik, O; Hamada, H; Lumniczky, K; Safrany, G, 2003) |
| "Malignant glioma is one of the most intractable tumors because of its invasiveness to surrounding brain tissue." | ( Cuevas, P; Díaz-González, D; Dujovny, M, 2003) |
| "Gliomas are primary central nervous system tumors that arise from astrocytes, oligodendrocytes, or their precursors." | ( Kapoor, GS; O'Rourke, DM, 2003) |
| "Gliomas are tumors of the central nervous system with a wide spectrum of different tumor types." | ( Laird, PW; Marczinek, K; Nürnberg, P; Rohde, K; Szymas, J; Thiel, G; Uhlmann, K; Vogel, S; Zeller, C, 2003) |
| "Gliomas are the most common malignant tumors in brain." | ( Edling, C; Elias, J; Lachmann, B; Marian, B; Noe, CR; Rolf, SH; Schuster, I, 2003) |
| "Gliomas are the most common types of brain tumors." | ( Dittmar, C; Garlip, G; Heiss, WD; Jacobs, AH; Winkeler, A, 2002) |
| "High-grade gliomas are usually of poor prognosis, and conventional radiotherapy, even combined with chemotherapy, still fails to improve the survival of patients." | ( Adam, JF; Balosso, J; Biston, MC; Bohic, S; Charvet, AM; Elleaume, H; Estève, F; Foray, N; Joubert, A, 2004) |
| "Malignant gliomas are among the most devastating of cancers and are a major cause of mortality in a young population with a median survival time of 9 months following cytoreductive surgery, radiotherapy and chemotherapy." | ( Das, UN, 2004) |
| "As cerebral gliomas are the main systemic tumours induced by 1,3-propane sultone experimentally, the occurrence of a glioblastoma among previously exposed persons appears conspicuous." | ( Bolt, HM; Golka, K, 2004) |
| "Malignant glioma is characterised by extensive neovascularisation, principally influenced by vascular endothelial growth factor (VEGF)." | ( Andersson, U; Bergenheim, AT; Bergh, A; Henriksson, R; Johansson, M; Sandström, M, 2004) |
| "High-grade gliomas are the most common primary brain tumors in adults." | ( Akdemir, H; Altinbas, M; Cihan, Y; Coskun, HS; Er, O; Kaplan, B; Karahacioglu, E; Kontas, O; Menku, A; Ozkan, M, 2004) |
| "Malignant glioma is a devastating brain tumor with no effective treatment." | ( Hurskainen, H; Immonen, A; Langford, G; Murray, N; Sandmair, A; Tyynelä, K; Vanninen, R; Vapalahti, M; Ylä-Herttuala, S, 2004) |
| "Malignant gliomas are highly lethal tumors that display striking genetic heterogeneity." | ( Bigner, DD; Cavenee, WK; Conrad, CA; Friedman, HS; Goudar, RK; Hjelmeland, MD; Keir, ST; Lane, HA; McLendon, RE; Reardon, DA; Reese, ED; Rich, JN; Shi, Q; Traxler, P; Wang, XF; Wikstrand, CJ, 2005) |
| "Childhood malignant gliomas are rare, but their clinical behavior is almost as aggressive as in adults, with resistance to therapy, rapid progression, and not uncommonly, dissemination." | ( Bozzi, F; Casanova, M; Cefalo, G; Collini, P; Ferrari, A; Fossati-Bellani, F; Gandola, L; Giangaspero, F; Locatelli, F; Luksch, R; Massimino, M; Meazza, C; Pignoli, E; Podda, M; Polastri, D; Ravagnani, F; Riva, D; Scaramuzza, D; Solero, C; Spreafico, F; Terenziani, M; Zecca, M, 2005) |
| "Gliomas are heterogeneous tumors with increased microvasculature, hypoxia, and necrosis." | ( Cha, S; Chang, SM; Crawford, F; Graves, EE; Li, X; Nelson, SJ; Vigneron, DB, 2005) |
| "Gliomas are resistant to most chemotherapeutic agents, and its mechanism is not known in detail." | ( Parent, AD; Tamaki, N; Yin, D; Zhang, JH, 2005) |
| "Human malignant gliomas are highly resistant to current therapeutic approaches." | ( Dziembowska, M; Ellert-Miklaszewska, A; Gaweda-Walerych, K; Kaminska, B; Zupanska, A, 2005) |
| "Because glioma is a disease with dismal prognosis and rapid progression, it is an attractive target for gene therapy." | ( Ali, S; Candolfi, M; Castro, MG; Cheng, Q; Curtin, JF; King, GD; Kupiec-Weglinski, J; Lassmann, H; Liu, C; Lowenstein, PR; Prieto, J; Puntel, M; Ribas, A; van Rooijen, N; Xiong, W, 2005) |
| "Malignant gliomas are among the most devastating human cancers." | ( Brem, H; Brem, S; Gallia, GL, 2005) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Gliomas are primary brain tumors with a complex biology characterized by antigenic and genomic heterogeneity and a propensity for invasion into normal brain tissue." | ( Benos, DJ; Bubien, JK; Colby, G; Esimai, O; Fuller, CM; Gillespie, GY; Jovov, B; Kovacs, GG; Mapstone, TB; Markert, JM; Pahwa, AK; Vila-Carriles, WH; Zhou, ZH, 2006) |
| "Malignant gliomas are highly invasive tumors which are lethal despite aggressive therapy." | ( Cattaneo, MG; Gentilini, D; Vicentini, LM, 2006) |
| "High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks." | ( Bajenaru, ML; Bock, NA; Clarke, L; Guha, A; Gutmann, DH; Henkelman, RM; Herlyn, D; Kaplan, D; Karim, Z; Lavoie, JF; Purev, E; Qian, B; Reti, R; Sabha, N; Scheidenhelm, DK; Shannon, P; Swoboda, R; Tong, A; Wei, Q, 2006) |
| "Gliomas are highly lethal neoplasms that cannot be cured by currently available therapies." | ( Auger, N; Dutrillaux, B; Idbaih, A; Legrier, ME; Poupon, MF; Sanson, M; Thillet, J; Wanherdrick, K, 2006) |
| "Gliomas are the most common type of primary brain tumor." | ( Norden, AD; Wen, PY, 2006) |
| "High-grade gliomas are characterized by rapid proliferation, angiogenesis, and invasive growth." | ( Hirschberg, H; Krasieva, T; Madsen, SJ; Sun, CH, 2006) |
| "Malignant gliomas are very difficult neoplasms for clinicians to treat." | ( Bohan, E; Brem, H; Hussain, N; Kleinberg, L; Lawson, HC; Olivi, A; Park, MC; Sampath, P; Weingart, J, 2007) |
| "Malignant gliomas are highly glycolytic and produce copious amounts of lactic acid, which is effluxed to the tumor microenvironment via lactate transporters." | ( Colen, CB; Galloway, MP; Marples, B; Mathupala, SP; Seraji-Bozorgzad, N; Sloan, AE, 2006) |
| "Gliomas are often resistant to the induction of apoptotic cell death as a result of the development of survival mechanisms during astrocyte malignant transformation." | ( Deleu, L; Di Piazza, M; Geletneky, K; Herrero Y Calle, M; Mader, C; Rommelaere, J; Schlehofer, J; Weber, E, 2007) |
| "High grade gliomas are the most frequent and malignant primary brain tumours in adults." | ( Laigle-Donadey, F; Sanson, M, 2006) |
| "Gliomas are extremely resistant to anticancer therapies resulting in poor patient survival, due, in part, to altered expression of antioxidant enzymes." | ( Robbins, ME; Smith, PS; Spitz, DR; Zhao, W, 2007) |
| "High-grade gliomas are a late complication of radiation to the central nervous system and may respond to chemotherapy." | ( Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G, 2007) |
| "Malignant gliomas are the most common and devastating primary tumors of the adult central nervous system." | ( Battastini, AM; Bavaresco, L; Bernardi, A; Braganhol, E; Wink, MR, 2007) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "Gliomas are the most common and devastating primary tumors of the central nervous system." | ( Battastini, AM; Bavaresco, L; Bernardi, A; Delgado-Cañedo, A; Jacques-Silva, MC; Lenz, G; Wink, MR, 2007) |
| "Low-grade gliomas are heterogeneous tumors with regard to the distribution of amino acid uptake and CBF." | ( Bärtschi, E; Hefti, M; Hofer, S; Roelcke, U; Treyer, V; Uhlmann, C; Wyss, MT, 2007) |
| "Gliomas are the most common and lethal primary tumors of the central nervous system (CNS)." | ( Cao, W; Jiang, X; Liu, E; Liu, W; Wu, J; Zhang, J; Zhang, X, 2007) |
| "Malignant gliomas are highly aggressive brain tumors that display many of these characteristics." | ( Shu, HK; Xu, K, 2007) |
| "Malignant gliomas are resistant to various proapoptotic therapies, such as radiotherapy and conventional chemotherapy." | ( Choi, KS; Kim, EH; Kim, MJ; Kim, SU; Kwon, HJ; Lee, SJ; Sohn, S, 2007) |
| "Gliomas are the most malignant of the primary brain tumors." | ( Battastini, AM; Bernardi, A; Braganhol, E; Tamajusuku, AS; Wink, MR, 2007) |
| "Glioma is a highly invasive, rapidly spreading form of brain cancer that is resistant to surgical and medical treatment." | ( Fan, XJ; Fu, YJ; Liang, AH; Liu, ZL; Xu, CG; Xu, QL; Yang, J; Yin, LT, 2007) |
| "High-grade gliomas are one of the most aggressive human tumors with <1% of patients surviving 5 years after surgery." | ( Badn, W; Darabi, A; Salford, LG; Siesjö, P; Smith, KE; Visse, E, 2007) |
| "Gliomas are tumors derived from glia or their precursors within the central nervous system." | ( Chiarini, LB; Erlich, RB; Kahn, SA; Lima, FR; Linden, R; Martins, RA; Martins, VR; Moura Neto, V; Muras, AG, 2007) |
| "High-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively." | ( Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Rogers, G; Somerville, M; Stein, K, 2008) |
| "Gliomas are one of the most malignant cancers." | ( Chelli, B; Costa, B; Da Pozzo, E; Evangelista, M; Gremigni, V; Lena, A; Martini, C; Rainaldi, G; Rechichi, M; Rossi, L; Salvetti, A; Spinetti, F, 2008) |
| "Highly malignant gliomas are characterized by rapid growth, extensive local tissue infiltration and the resulting overall dismal clinical outcome." | ( Dai, G; Deisboeck, TS; Huang, S; Rosen, BR; Stemmer-Rachamimov, A; Vader, D; Wang, Z; Weitz, DA, 2008) |
| "Malignant gliomas are highly aggressive tumors of the central nervous system that rely on production of growth factors for tumor progression." | ( Gillespie, GY; King, PH; Li, X; Li, Y; Lu, L; Shacka, JJ; Suswam, E; Zhang, X; Zheng, L, 2008) |
| "Rat C6 glioma is a chemo-resistant experimental brain tumor that is difficult to treat with various drug combinations." | ( Aktas, E; Bilir, A; Bonavida, B; Erguven, M; Oktem, G; Ozdemir, A; Uslu, A, 2008) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | ( Kleinberg, LR; Lin, SH, 2008) |
| "Gliomas are the most common and devastating tumors of the central nervous system." | ( Battastini, AM; Bavaresco, L; Bernardi, A; Figueiró, F; Frozza, RL; Guterres, SS; Jäger, E; Pohlmann, AR; Salbego, C, 2008) |
| "Gliomas are the most common primary brain tumor in adults, but the efficacy of chemotherapy is limited." | ( Fang, SH; Huang, XJ; Li, CT; Lu, YB; Wei, EQ; Zhang, WP, 2008) |
| "Gliomas are the most common type of primary tumor in the human central nervous system." | ( Gu, J; Li, G; Shen, J; Su, Y; Sun, T; Tian, Z; Zhang, J; Zhang, X, 2008) |
| "Malignant gliomas are the most common primary intrinsic brain tumors and are highly lethal." | ( Choi, Y; Liang, XJ; Park, JK; Sackett, DL, 2008) |
| "Malignant gliomas are the most common and devastating primary tumors in the brain and, despite treatment, patients with these tumors have a poor prognosis." | ( Battastini, AM; Bavaresco, L; Bernardi, A; Braganhol, E; Cappellari, AR; Delgado-Cañedo, A; Farias, PF; Rockenbach, L; Wink, MR, 2008) |
| "Malignant glioma is the most commonly occurring primary malignant brain tumor." | ( Desjardins, A; Friedman, HS; Reardon, DA; Vredenburgh, JJ, 2009) |
| "Glioma is the most common primary adult brain tumor with poor prognosis because of the spreading of tumor cell to the other regions of brain easily." | ( Fu, WM; Lee, MJ; Lu, DY; Yeh, WL, 2009) |
| "Malignant gliomas are common primary tumors of the central nervous system." | ( Akiyama, Y; Bögler, O; Fujiwara, K; Kondo, S; Moritake, K; Shingu, T; Shinojima, N; Tamada, Y; Yokoyama, T, 2009) |
| "Malignant gliomas are the most common and devastating primary tumors of the central nervous system." | ( Delgado-Cañedo, A; Frozza, RL; Gaelzer, MM; Gerhardt, D; Henriques, AT; Horn, AP; Lenz, G; Pelegrini, AL; Salbego, C, 2009) |
| "Malignant gliomas are the most frequent primary brain tumors in adults." | ( Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM, 2008) |
| "Gliomas are primary brain tumors with poor prognosis that exhibit frequent abnormalities in phosphatidylinositol 3-kinase (PI3 kinase) signaling." | ( Bjerke, L; Clarke, PA; Eccles, SA; Guillard, S; Mohri, Z; Raynaud, F; Te Poele, R; Valenti, M; Workman, P, 2009) |
| "High grade gliomas are one of the most difficult cancers to treat and despite surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is poor." | ( Amoroso, R; Bartoli, B; Benvenuti, L; Gagliardi, R; Gremigni, V; Lena, A; Rechichi, M; Rossi, L; Salvetti, A; Scarcelli, V; Vecchio, D, 2009) |
| "Malignant gliomas are the most common primary brain tumors." | ( Billiar, TR; Jeong, M; Jeun, SS; Kim, BM; Kim, CY; Ko, Y; Kwon, YS; Park, SH; Robbins, PD; Seol, DW; Song, KW, 2009) |
| "Malignant glioma is resistant to the induction of apoptosis, resulting in a subsequent failure of chemotherapy in clinical treatment strategies." | ( Shiguang, Z; Tianhu, Z; Xinghan, L, 2010) |
| "Malignant gliomas are common and aggressive brain tumors in adults." | ( Huang, Y; Li, Y; Ou, Y; Qiu, P; Shu, M; Xie, J; Yan, G; Zhu, W, 2009) |
| "High grade gliomas are known to release excitotoxic concentrations of glutamate, a process thought to contribute to their malignant phenotype through enhanced autocrine stimulation of their proliferation and destruction of the surrounding nervous tissue." | ( Abarca-Quinones, J; Gallez, B; Hermans, E; Jordan, BF; Maloteaux, JM; Vanhoutte, N, 2009) |
| "Malignant gliomas are characterized by a short median survival which is largely impacted by the resistance of these tumors tochemo- and radiotherapy." | ( Brodie, C; Decarvalho, A; Finniss, S; Kalkanis, SN; Lomonaco, SL; Mikkelsen, T; Umansky, F; Xiang, C, 2009) |
| "Malignant gliomas are notoriously resistant to treatment and the survival time of patients is between 3-8 years for low-grade and anaplastic gliomas and 6 - 12 month for glioblastoma." | ( Amberger-Murphy, V, 2009) |
| "Malignant gliomas are the most frequent primary brain tumors in adults." | ( Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P, 2009) |
| "Glioma is the most frequent and malignant primary human brain tumor with dismal prognosis despite multimodal therapy." | ( Dillenburg-Pilla, P; Filippi-Chiela, EC; Horn, F; Lenz, G; Salbego, C; Zamin, LL, 2009) |
| "Gliomas are the most common adult primary brain tumors, and the most malignant form, glioblastoma multiforme, is invariably fatal." | ( Koty, Z; Lau, CJ; Nalbantoglu, J, 2009) |
| "Glioma is the most common primary brain tumor with poor prognosis." | ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "Gliomas are the most common type of primary intracranial tumor." | ( Cheng, C; Shen, A; Sun, L; Wang, Y; Zhao, Y; Zou, L, 2009) |
| "Malignant gliomas are highly infiltrative tumours with a fatal prognosis." | ( Fonyuy, N; Horn, P; Koch, A; Misch, M; Plotkin, M; Stockhammer, F, 2009) |
| "Malignant gliomas are the most common primary brain tumors in adults." | ( D'Elia, A; Formichella, AI; Frati, A; Salvati, M, 2009) |
| "Brain edema in gliomas is an epiphenomenon related to blood-brain-barrier (BBB) breakdown in which endothelial nitric oxide synthase (eNOS) plays a key role." | ( Argandoña, EG; Bengoetxea, H; Bulnes, S; Lafuente, JV; Leis, O; Ortuzar, N, 2010) |
| "Malignant gliomas are among the most intractable brain cancers." | ( Chen, FX; Duan, Y; Ji, Y; Qian, Y; Ren, WW; Shen, D; Xu, S; Yang, Y; Zong, Y, 2009) |
| "Diffuse pontine gliomas are a pediatric brain tumor that is fatal in nearly all patients." | ( Foreman, NK; Liu, AK; Macy, ME, 2009) |
| "High grade gliomas are aggressive cancers that are not well addressed by current chemotherapies, in large measure because these drugs do not curtail the diffuse invasion of glioma cells into brain tissue surrounding the tumor." | ( An, Z; Choy, ML; Gluck, CB; Kaufman, LJ, 2010) |
| "Glioma is the most common type of brain tumors in adults, and treatment of high-grade gliomas is still palliative." | ( Choi, TG; Choi, WJ; Ding, Y; Ha, J; Han, X; Huh, YB; Kim, SS; Kim, YH; Kim, YJ; Yoon, SH, 2010) |
| "Glioma is a common malignant tumor of the human neural system, and Wnt signaling activation is closely connected with glioma malignancy." | ( Chen, YY; Li, BA; Liu, XY; Ma, YH; Shen, SH; Tan, GW; Wang, HD; Wang, ZX; Zhu, HW, 2011) |
| "Gliomas are tumors of the central nervous system derived from glial cells." | ( Acosta, G; Caire, F; Chaunavel, A; De Armas, R; Denizot, Y; Durand, K; Guillaudeau, A; Labrousse, F; Marin, B; Moreau, JJ; Pebet, M; Robert, S; Weinbreck, N, 2010) |
| "Nasal glioma is a rare congenital midline malformation composed of heterotopic masses of neuroglial tissue." | ( Brasseur-Daudruy, M; Cellier, C; Grzegorczyk, V; Labadie, G; Verspyck, E, 2010) |
| "Glioma is the most common primary adult brain tumor, with a poor prognosis because of the ease with which tumor cells spread to other regions of the brain." | ( Huang, SM; Leung, YM; Lu, DY; Wong, KL, 2010) |
| "Malignant gliomas are highly lethal neoplasms that cannot be cured with currently available therapies." | ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2010) |
| "High-grade gliomas are among the most lethal of all cancers." | ( Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M, 2010) |
| "Gliomas are regionally heterogeneous tumors." | ( Hirata, K; Kobayashi, H; Murata, J; Shiga, T; Tanaka, S; Terasaka, S; Yamaguchi, S, 2011) |
| "Brain glioma is a malignant tumor which needs surgery followed by chemotherapy." | ( Liu, Y; Shang, X; Xue, Y; Zhang, Z, 2010) |
| "Malignant glioma is a common and severe primary brain tumor with a high recurrence rate and an extremely high mortality rate within 2 years of diagnosis, even when surgical, radiological, and chemotherapeutic interventions are applied." | ( Chen, JP; Chen, PY; Chen, SM; Chu, PC; Chuang, JI; Feng, LY; Hsueh, C; Hua, MY; Huang, CY; Liu, HL; Lu, YJ; Lyu, LA; Ma, YH; Shin, JW; Tsai, HC; Tseng, IC; Wang, JJ; Wei, KC; Wu, T; Yang, HW; Yen, TC, 2010) |
| "A hallmark of gliomas is their rapid proliferation and destruction of vital brain tissue, a process in which excessive glutamate release by glioma cells takes center stage." | ( Eyüpoglu, IY; Hahnen, E; Hauke, J; Savaskan, NE; Seufert, S; Tränkle, C, 2011) |
| "Gliomas are the most common primary intracranial tumors." | ( Bian, A; Bo, X; Ding, L; Jiang, J; Jin, X; Li, Z; Liu, C; Liu, D; Sun, X; Tu, Y; Wang, X; Wang, Z, 2011) |
| "Gliomas are the most common primary brain tumors in India." | ( Arunkumar, R; Devan, S; Palani, M; Vanisree, AJ, 2011) |
| "Malignant glioma is one of the most intractable diseases in the human body." | ( Fujioka, K; Inaba, N; Ishizawa, S; Kimura, M; Manome, Y; Shibasaki, T; Watanabe, M, 2010) |
| "Gliomas are a common type of primary brain tumor with glioblastoma multiforme accounting for the majority of human brain tumors." | ( Chang, HF; Chen, HJ; Huang, WT; Yang, LL, 2010) |
| "Malignant gliomas are characterized by high invasive potential and strong angiogenic ability." | ( Nakabayashi, H; Shimizu, K, 2011) |
| "Gliomas are the most common primary tumors of the central nervous system." | ( Chen, J; Lan, Q; Ma, Y; Shao, B; Shen, A; Shi, J; Shi, W; Wan, Z, 2011) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| "Malignant gliomas are the most common primary tumors that arise from glial cells and are characterized by extensive invasiveness and rapid progression." | ( Cheng, YK; Hsiao, IT; Lin, KJ; Wang, TC; Wey, SP; Yen, TC, 2011) |
| "Malignant glioma is the most common primary brain tumor." | ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Malignant gliomas are the most destructive type of brain cancer." | ( Kim, JH; Lee, WH; Suk, K; Zheng, LT, 2011) |
| "Malignant gliomas are diffuse infiltrative growing tumors with a poor prognosis despite treatment with a combination of surgery, radiotherapy and chemotherapy." | ( Mayer, D; Noell, S; Ritz, R; Strauss, WS; Tatagiba, MS, 2011) |
| "Malignant gliomas are the most common and lethal intracranial tumors, and differentiation therapy shows great potential to be a promising candidate for their treatment." | ( He, S; Huang, Y; Li, Y; Ou, Y; Yan, G; Zhou, Y; Zhu, W, 2011) |
| "Malignant gliomas are aggressive and angiogenic tumors with high VEGF content." | ( Hou, H; Jounaidi, Y; Khan, N; Lariviere, JP; Mupparaju, S; Swartz, H, 2011) |
| "We show that gliomas are attracted in a chemotactic manner to epidermal growth factor (EGF)." | ( Barclay, TT; Bomben, VC; Sontheimer, H; Turner, KL, 2011) |
| "Gliomas are the most common primary brain tumor, and their treatment is still a challenge." | ( Avramidis, D; Cruz, M; Delwar, ZM; Follin, E; Hua, Y; Paulsson, KM; Siden, Å; Yakisich, JS, 2012) |
| "Gliomas are the most aggressive of all human malignancies." | ( Chiu, HW; Ho, YS; Wang, YJ, 2011) |
| "High-grade gliomas are the most common primary tumors in the central nervous system (CNS) in adults." | ( Bogdahn, U; Hau, P; Jachimczak, P; Schlaier, J, 2011) |
| "Gliomas are characterized by excessive proliferation, diffuse infiltration and immunosuppression." | ( Jing, Z; Qiu, B; Wang, Y; Wu, A; Zhang, D, 2011) |
| "Malignant gliomas are aggressive brain tumors with limited therapeutic options, and improvements in treatment require a deeper molecular understanding of this disease." | ( Bredel, M; Chandler-Militello, D; Eyler, CE; Forrester, MT; Goldman, SA; Hjelmeland, AB; Lathia, JD; Lee, J; MacSwords, JM; McLendon, RE; Misuraca, KL; Rich, JN; Sloan, AE; Stamler, JS; Wu, Q; Yan, K, 2011) |
| "Recurrent gliomas are usually histologically high grade; either due to recurrence of a de novo high-grade primary or anaplastic transformation in case of low-grade tumors." | ( Bal, C; Julka, PK; Kumar, R; Malhotra, A; Santra, A; Sharma, P, 2011) |
| "Malignant gliomas are one of the most devastating and incurable tumors." | ( Agarwal, C; Agarwal, R; Deep, G; Kavitha, CV, 2011) |
| "Malignant gliomas are the most common in central nervous system cancer." | ( Li, L; Li, Y; Liu, W; Lv, G; Wang, B, 2011) |
| "Malignant glioma is an invasive disease of the central nervous system." | ( Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Ishizawa, S; Kimura, M; Manome, Y; Saito, H, 2011) |
| "Glioma is the most common type of brain tumor, and has the worst prognosis in human malignancy." | ( Matsuo, H; Nawashiro, H; Nomura, N; Osada, H; Otani, N; Shinomiya, N; Takeuchi, S; Toyooka, T; Wada, K, 2012) |
| "Gliomas are the most common and devastating type of primary brain tumor." | ( Battastini, AM; Bergamin, LS; Bernardi, A; Braganhol, E; Calixto, JB; Campesato, LF; Campos, MM; Cappellari, AR; Edelweiss, MI; Morrone, FB; Robson, SC; Sévigny, J; Wink, MR; Zanin, RF, 2012) |
| "Gliomas are the most common brain tumors in adults and account for more than half of all brain tumors." | ( Seol, DW, 2011) |
| "Glioma is the most common malignant cancer affecting the central nerve system, with dismal prognosis." | ( Chen, J; Shu, M; Wu, S; Yan, G; Zhang, H; Zhou, Y; Zhu, W, 2012) |
| "Gliomas are the most common and devastating tumors of the central nervous system (CNS)." | ( Battastini, AM; Campos, MM; Chiaradia, LD; Chirardia, LD; Filippi-Chiela, E; Leal, PC; Lenz, G; Mascarello, A; Mielcke, TR; Morrone, FB; Nunes, RJ; Yunes, RA; Zanin, RF, 2012) |
| "Gliomas are devastating tumors of the brain resistant to therapies." | ( Capocefalo, A; Cavirani, S; D'Avella, D; Denaro, L; Donofrio, G; Franceschi, V; Mucignat-Caretta, C; Redaelli, M, 2012) |
| "Gliomas are the most common and devastating central nervous system neoplasms." | ( Brann, DW; Brenner, A; Gonugunta, VK; Nair, BC; Sareddy, GR; Tekmal, RR; Vadlamudi, RK; Zhang, QG, 2012) |
| "Malignant gliomas are associated with alteration in EGF/EGFR signaling." | ( da Fonseca, CO; da Silveira, Fd; de Amorim, LM; de Palmer Paixão, IC; Lopes, Bde A; Quirico-Santos, T, 2012) |
| "Glioma is a highly complex brain tumor characterized by the dysregulation of proteins and genes that leads to tumor metastasis." | ( Alapati, K; Gondi, CS; Gopinath, S; Gorantla, B; Rao Malla, R; Rao, JS, 2013) |
| "Malignant glioma is the most devastating and aggressive tumor in brain, characterized by rapid proliferation and diffuse invasion." | ( Chen, J; Hu, J; Li, J; Lin, Y; Qiu, P; Su, X; Wang, Y; Wu, S; Yan, G; Zhang, H; Zhang, J; Zhao, S; Zhou, Y; Zhu, W, 2012) |
| "Malignant gliomas are highly resistant to current therapies that induce apoptosis, thus induction of the alternative cell death is an attractive strategy." | ( Ciechomska, IA; Gabrusiewicz, K; Kaminska, B; Szczepankiewicz, AA, 2013) |
| "Gliomas are the most lethal tumors of central nervous system." | ( Battastini, AM; Bogo, MR; Borges, MC; Braga Filho, A; Campos, MM; Gehring, MP; Lenz, G; Morrone, FB; Pereira, TC; Zanin, RF, 2012) |
| "Glioma is one of the most common primary brain tumors." | ( Guo, C; Li, H; Liu, C; Ma, C; Shi, Y; Song, X; Wang, Q; Wang, X; Zhang, L; Zhang, X; Zhu, F, 2012) |
| "Glioma is one of the most malignant tumors in the central nervous system." | ( Hao, X; Li, W; Ren, X; Wang, P; Yin, Q; Yu, J, 2012) |
| "Malignant gliomas are primary brain tumors with high rates of morbidity and mortality; they are the fourth most common cause of cancer death." | ( Chen, D; Chen, X; Dong, M; Fu, X; Li, Q; Li, S; Liu, X; Qiu, T; Sun, H; Wan, T; Wu, Q, 2012) |
| "Gliomas are the most devastating of primary adult malignant brain tumors." | ( Ang, BT; Brooks, HB; Campbell, RM; Chong, YK; Foong, CS; Sandanaraj, E; Tang, C, 2012) |
| "Glioma is the most common primary adult brain tumor with poor prognosis because of the ease of spreading tumor cells to other regions of the brain." | ( Huang, SM; Lu, DY; Tan, TW; Tsai, CF; Yeh, WL, 2012) |
| "Malignant glioma is the most common primary brain tumor and accounts for the majority of diagnoses." | ( Date, I; Fujii, K; Ichikawa, T; Kurozumi, K; Onishi, M, 2012) |
| "Gliomas are aggressive brain tumours that, despite advances in multimodal therapies, continue to portend a dismal prognosis." | ( Atkins, RJ; Dimou, J; Drummond, KJ; Hovens, CM; Kaye, AH; Morokoff, AP; Paradiso, L, 2012) |
| "High-grade gliomas are some of the most lethal forms of human cancer, and new clinical biomarkers and therapeutic targets are highly needed." | ( Dahlrot, RH; Hansen, S; Hermansen, SK; Kristensen, BW; Nielsen, BS, 2013) |
| "Gliomas are the most common primary brain tumors in adults and have a poor prognosis." | ( Binh, NH; Hara, A; Hatano, Y; Hirata, A; Kobayashi, K; Kuno, T; Satoh, K; Takamatsu, M; Tomita, H, 2013) |
| "Low-grade gliomas are generally characterized by a relatively high concentration of N-acetylaspartate, low level of choline and absence of lactate and lipids." | ( Bulik, M; Jancalek, R; Mechl, M; Skoch, A; Vanicek, J, 2013) |
| "Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
| "Malignant gliomas are highly invasive brain cancers that carry a dismal prognosis." | ( Cuddapah, VA; Sontheimer, H; Turner, KL, 2013) |
| "Malignant glioma is an aggressive tumour commonly associated with a dismal outcome despite optimal surgical and radio-chemotherapy." | ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| "Gliomas are primary brain cancers that spread exclusively within the brain, frequently migrating along blood vessels to which they are chemotactically attracted by bradykinin." | ( Cuddapah, VA; Seifert, S; Sontheimer, H; Turner, KL, 2013) |
| "Gliomas are notoriously recurrent and highly infiltrative, and have been shown to arise from stem-like cells." | ( Ang, BT; Chong, YK; Clement, MV; Koh, GR; Koh, LW; Kon, OL; Ng, FS; Ng, IH; Ng, WH; Pervaiz, S; Phong, M; Sandanaraj, E; Tang, CS; Toh, TB; Tucker-Kellogg, G, 2013) |
| "Brain glioma is the most common malignant intracranial tumor and has become the focus of research on diseases of the central nervous system due to its high incidence and poor prognosis." | ( Wang, A; Wu, W; Zhang, B; Zhang, J, 2013) |
| "Gliomas are resistant to radiation therapy, as well as to TNFα induced killing." | ( Ghildiyal, R; Mehta, VS; Sen, E; Sinha, S, 2013) |
| "The development of glioma is a complex process which may be influenced by many factors including the epidermal growth factor (EGF) gene polymorphism." | ( Hu, M; Liu, W; Shi, H; Xu, Z, 2013) |
| "High-grade gliomas are extremely difficult to treat because they are invasive and therefore not curable by surgical resection; the toxicity of current chemo- and radiation therapies limits the doses that can be used." | ( Aboody, KS; Annala, AJ; Aramburo, S; Badie, B; Barish, ME; Blanchard, S; Brown, CE; Couture, LA; D'Apuzzo, M; Frank, RT; Garcia, E; Gutova, M; Kim, SU; Metz, MZ; Moats, RA; Najbauer, J; Portnow, J; Synold, TW; Valenzuela, VV, 2013) |
| "Malignant gliomas are the most frequently occurring, devastating primary brain tumors, and are coupled with a poor survival rate." | ( Juratli, TA; Krex, D; Schackert, G, 2013) |
| "Gliomas are the most common form of primary brain tumor with the highest mortality rates." | ( Wang, Q; Yang, P; Zhu, Y, 2013) |
| "Glioma is the most common primary brain tumor and causes a disproportionate level of morbidity and mortality across a wide range of individuals." | ( Jiang, L; Mu, K; Xie, H; Xu, H; Yang, X; Zhao, Y; Zhou, Q; Zhu, W; Zhu, Y, 2013) |
| "Malignant gliomas are the leading cause of morbidity and mortality in brain and central nervous system tumors." | ( Gu, J; He, W; Kuang, Y; Liu, E; Xing, X, 2013) |
| "Malignant gliomas are the most devastating and aggressive brain tumors affecting the central nervous system." | ( Gao, X; Leng, T; Ou, Y; Qiu, P; Shu, M; Sun, H; Yan, G; Zheng, X; Zhou, Y; Zhu, W, 2013) |
| "Malignant gliomas are the most common and most aggressive primary brain tumor, and for which differentiation therapy has emerged as a promising candidate strategy." | ( Cai, M; Guo, Q; Hu, R; Li, Y; Li, Z; Qian, C; Wang, Q; Wang, Y; You, Q; Zhang, Y, 2013) |
| "Glioma is the most common primary intracranial tumour." | ( Chen, X; Dai, Y; Jiang, X; Liu, H; Liu, J; Xia, H; Yao, C; Zhang, L; Zhao, D, 2013) |
| "Malignant gliomas are the most common adult brain cancers." | ( Elsherbiny, ME; Emara, M; Godbout, R, 2013) |
| "Human gliomas are associated with high rates of morbidity and mortality." | ( Lan, Q; Liu, S; Sun, J, 2013) |
| "Malignant gliomas are the most common primary intracranial tumors with a dismal prognosis." | ( Chen, Z; Gu, N; Huang, Z; Liu, P; Wang, C; Wu, H; Xu, R; Zang, F, 2013) |
| "Gliomas are a group of heterogeneous primary central nervous system tumors arising from glial cells." | ( Chen, LK; Gu, B; Yi, GQ, 2014) |
| "Glioma is one of the most common brain tumors in adults." | ( Hirata, K; Houkin, K; Kobayashi, H; Shiga, T; Terasaka, S; Yamaguchi, S, 2013) |
| "Gliomas are the largest group of central nervous system tumors and despite of clinical treatments death rate is very high." | ( Kabadere, S; Kus, G; Oztopcu-Vatan, P; Uyar, R, 2013) |
| "Gliomas are the most common primary brain tumors in adults and a significant cause of cancer-related mortality." | ( Bao, ZS; Chen, L; Jiang, T; Li, MY; Liu, YW; Wang, HJ; Wang, JY; Yan, W; Zhang, CB; Zhang, W, 2014) |
| "Malignant gliomas are relentless tumors that offer a dismal clinical prognosis." | ( Robert, SM; Sontheimer, H, 2014) |
| "Glioma is a malignant tumor with high mortality but effective therapy has not yet been developed." | ( Chen, FX; Ding, G; Ji, YH; Li, H; Li, Z; Wu, Y; Xu, YM; Yu, KK; Zhang, C, 2014) |
| "Gliomas are the most frequent primary brain tumors in adults." | ( Chinot, O; Crétel, E; Retornaz, F; Rousseau, F; Tabouret, E; Tassy, L, 2013) |
| "Glioma is an increasing threat to humans' health." | ( Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Wang, Y; Wei, Y, 2014) |
| "Gliomas are the most common and aggressive of brain tumors in adults." | ( Chandrika, G; Dawood, P; Hegde, AS; Jagtap, JC; Natesh, K; Ranade, D; Shah, RD; Shastry, P; Shiras, A, 2014) |
| "Malignant gliomas are common primary tumors of the central nervous system." | ( Gong, X; Liu, R; Shen, S; Wang, Z; Zhang, Y, 2014) |
| "Glioma is an extremely aggressive and lethal form of brain tumor, and thus the study of the molecule mechanism underlying glioma remains very important." | ( Chen, J; Hu, G; Hu, Y; Li, J; Li, Y; Shen, B; Yan, W, 2013) |
| "Malignant glioma is one of the most challenging central nervous system (CNS) diseases, which is typically associated with high rates of recurrence and mortality." | ( Fan, CH; Liu, HL; Ting, CY; Yeh, CK, 2014) |
| "Malignant gliomas are the most common type of primary malignant brain tumors." | ( Fortin, D; Poirier, MB; Roy, LO, 2015) |
| "The treatment of glioma is a great challenge because of the existence of the blood-brain barrier (BBB)." | ( Chen, J; Gao, H; He, Q; Kuang, Q; Liu, Y; Mei, L; Ran, R; Tang, J; Zhang, Q; Zhang, Z, 2014) |
| "Glioma is the most common brain malignancy with poor prognosis." | ( Chen, K; Chen, X; Gan, D; Ke, Y; Li, Y; Peng, Y; Xu, D, 2014) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Gliomas are primary brain tumours." | ( Benadiba, M; Colquhoun, A; DE Oliveira Silva, D; Miyake, JA; Ribeiro, G, 2014) |
| "Invasive brain glioma is the most lethal type of cancer and is highly infiltrating." | ( Ju, RJ; Li, XT; Li, XY; Lou, JN; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhao, Y, 2014) |
| "The treatment for glioma is one of the most challenging problems and therapeutic effect of glioma is often limited due to poor penetration into the tumor tissue." | ( Fang, X; Lv, L; Wang, B; Wang, Z; Wu, L; Xin, H; Xu, Q; Zhao, Y, 2014) |
| "A feature of many gliomas is the amplification of the epidermal growth factor receptor (EGFR), resulting in its overexpression." | ( Adams, TE; Donoghue, JF; Gottardo, NG; Greenall, SA; Johns, TG, 2015) |
| "Glioma is one of the most aggressive and lethal human brain tumors." | ( Chen, Q; Jiang, BH; Jiang, C; Jiang, T; Kang, C; Li, C; Li, H; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, Z; Wang, L; Wang, X; You, Y, 2014) |
| "Malignant gliomas are common primary brain tumors with dismal prognosis." | ( Chen, YS; Chen, ZH; Chen, ZP; Gao, WC; Guo, CC; Ke, C; Li, X; Lin, FH; Lv, YC; Mou, YG; Sai, K; Wang, J; Yang, QY; Zeng, J; Zhang, XH; Zhong, MG, 2014) |
| "Malignant gliomas are heavily infiltrated by immature myeloid cells that mediate immunosuppression." | ( Kosaka, A; Ohkuri, T; Okada, H, 2014) |
| "Malignant gliomas are highly invasive tumours that use the perivascular space for invasion and co-opt existing vessels as satellite tumour form." | ( Ellis-Davies, G; Kimbrough, IF; Robel, S; Robert, SM; Sontheimer, H; Watkins, S, 2014) |
| "Brain gliomas are highly epileptogenic." | ( Baulac, M; Bielle, F; Capelle, L; Chazal, G; Cresto, N; Devaux, B; Duyckaerts, C; Huberfeld, G; Kourdougli, N; Le Van Quyen, M; Miles, R; Pallud, J; Pellegrino, C; Rivera, C; Varlet, P, 2014) |
| "Glioma is the most malignant brain tumor that has the ability to migrate and invade the CNS." | ( Chen, Y; Chou, WC; Ding, YM; Wu, YC, 2014) |
| "Gliomas are the most common malignant brain tumors in adults." | ( Bogo, MR; Campos, MM; Erig, TC; Morrone, FB; Nicoletti, NF; Pereira, TC; Zanin, RF, 2014) |
| "Gliomas are some of the most aggressive types of cancers but the blood-brain barrier acts as an obstacle to therapeutic intervention in brain-related diseases." | ( Grover, A; Hirani, A; Pathak, Y; Sutariya, V, 2014) |
| "Diffuse brainstem glioma is a rare disease in adults." | ( Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G, 2014) |
| "Glioma is the most malignant tumor of the central nervous system." | ( Chen, Y; Kung, HN; Kuo, MF; Peng, YS; Syu, JP; Wang, SD; Wang, SM; Yang, SH, 2014) |
| "Malignant gliomas are among the deadliest primary brain tumors." | ( Kraljik, N; Najbauer, J; Németh, P, 2014) |
| "Gliomas are the most frequent primary brain tumors." | ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Malignant glioma is a common and lethal primary brain tumor in adults." | ( Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y, 2015) |
| "Malignant gliomas are characterized by neurodegenerative actions leading to the destruction of surrounding brain parenchyma." | ( Buchfelder, M; Eyüpoglu, IY; Fan, Z; Hore, N; Rauh, M; Savaskan, NE; Seufert, S; Wolf, IM, 2014) |
| "Glioma is one of the most prevalent types of brain tumor and is associated with the highest mortality rate of all CNS cancers." | ( Li, X; Wang, Q; Yang, P; Zhu, Y, 2014) |
| "High-grade gliomas are amongst the most deadly human tumors." | ( Bogdahn, U; Bosserhoff, AK; Brawanski, A; Hau, P; Heudorfer, F; Leukel, P; Meyer, K; Moeckel, S; Proescholdt, M; Riemenschneider, MJ; Seliger, C; Spang, R; Stangl, C; Vollmann-Zwerenz, A, 2014) |
| "Gliomas are the most malignant and aggressive primary brain tumor in adults." | ( Chen, J; Cui, D; Ni, L; Shi, J; Shi, W; Sun, B; Zuo, H, 2015) |
| "High-grade glioma is the most common malignant primary brain tumor among adults, and the outcome is poor." | ( Forsberg-Nilsson, K; Kundu, S; Xiong, A, 2014) |
| "Glioma is one of the most common tumors in China and chemotherapy is critical for its treatment." | ( Jiang, Y; Li, Q; Liu, MY; Qi, LS; Wang, HO; Yang, P; Zhang, GD; Zhang, L; Zhu, Y, 2014) |
| "Glioma is the most common primary brain tumor among adults." | ( Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S, 2015) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Glioma is one of the most common malignancies in the world." | ( Ge, N; Gong, AJ; Gong, LL; Liang, H; Lu, LX; Yao, WC, 2015) |
| "High-grade glioma is one of the most aggressive cancers in adult humans and long-term survival rates are very low as standard treatments for glioma remain largely unsuccessful." | ( Dalgleish, AG; Liu, WM; Scott, KA, 2014) |
| "Glioma is resistant to the apoptotic effects of chemotherapy and the mechanism underlying its chemoresistance is not currently understood." | ( Li, P; Liu, H; Qian, C; Shi, L; Wang, Y; Yan, W; You, Y; Zhang, J, 2015) |
| "Glioma is still hard to be treated due to their complex microenvironment." | ( Chen, J; Cun, X; Gao, H; He, Q; Hu, G; Ruan, S; Yang, Y; Yuan, M; Zhang, L; Zhang, Q, 2015) |
| "Gliomas are the most common and malignant primary brain tumours and are associated with a poor prognosis despite the availability of multiple therapeutic options." | ( Cui, YK; Jiang, Q; Mei, JP; Pan, HC; Yu, Y; Zhao, WJ, 2015) |
| "Glioma is the most common malignant and fatal primary tumor in the central nervous system in adults." | ( Huo, L; Tang, G; Wu, J; Xiao, G, 2015) |
| "Glioma is the most common malignant intracranial tumors." | ( Han, JS; Ji, SP; Jia, M; Li, AM; Liu, YX; Zhang, XH; Zhao, M, 2014) |
| "Malignant gliomas are a common type of primary tumor of the central nervous system." | ( Cui, XG; Hu, J; Liu, JH; Pan, JM; Shi, HZ; Wang, GB; Xia, GW; Xue, K; Zhou, L, 2015) |
| "Glioma is an aggressive tumor with poor prognosis." | ( Chen, C; Deng, Q; Dong, X; Jia, W; Nie, X; Xu, C; Xu, R; Zhang, M, 2015) |
| "High-grade gliomas are aggressive, incurable tumors characterized by extensive diffuse invasion of the normal brain parenchyma." | ( Alves, M; Castel-Branco, M; Esteves, S; Stummer, W, 2015) |
| "Glioma is the most aggressive form of primary brain tumor, with dismal patient outcome and no effective therapeutic approaches available." | ( Han, Z; Hou, K; Zhang, X; Zhang, Y; Zhao, J; Zhu, X, 2015) |
| "Malignant glioma is one of the most devastating tumors in adults with poor patient prognosis." | ( Alleyne, CH; Dhandapani, KM; Prasad, N; Sukumari-Ramesh, S; Vender, JR, 2015) |
| "Glioma is the most common form of primary malignant brain cancers." | ( Li, H; Liu, Y; Lu, S; Shi, L; Sun, X; Wang, X; Wang, Y; Zhang, B; Zhang, H; Zhao, C, 2015) |
| "Glioma is the most common malignant tumors in adult brains, and Notch signaling pathway plays an important role in cell differentiation." | ( Li, C; Liu, H; Shan, X; Yao, J; Zheng, K, 2015) |
| "Malignant glioma is the most prevalent and lethal primary brain tumor." | ( Camorani, S; Cerchia, L, 2015) |
| "Tectal glioma is a midbrain tumor." | ( Burzynski, GS; Burzynski, SR; Janicki, TJ; Marszalek, A, 2015) |
| "Glioma is a type of aggressive malignant tumour with no effective systematic therapy so far." | ( Chen, M; Jin, B; Li, X; Pei, S; Ping, G; Wang, Z; Zhao, X; Zhou, W; Zhou, X, 2016) |
| "Glioma is most common cancer type of central nervous system in adults and the most lethal in children." | ( Carvalho, I; Costa, P; Ferreira, D; Marques, C; Martins, S; Mendes, B; Sarmento, B, 2015) |
| "Malignant glioma is the most common intracranial tumor with a dismal prognosis." | ( Gu, N; Huang, Z; Jin, H; Lin, J; Liu, P; Wang, C; Wen, L; Wu, H; Zhao, P, 2015) |
| "Malignant gliomas are the most common type of primary malignancy of the central nervous system, with a poor prognosis." | ( Cui, Q; Gao, G; Gao, X; Li, X; Wang, Y; Xu, Y; Zhang, J; Zhou, Q, 2015) |
| "High-grade gliomas are refractory to the current mode of treatment primarily due to their inherent resistance to cell death." | ( Harmalkar, M; Kazi, S; Shirsat, NV; Upraity, S, 2015) |
| "Malignant gliomas are the most common malignant tumors in the central nervous system (CNS)." | ( Huang, Y; Lin, J; Niu, T; Zhang, L; Zhang, Y; Zhong, W; Zhu, H, 2015) |
| "Glioma is one of the most common intracranial tumors, and the prognosis is poor, although more and more treatments are employed." | ( Ma, L; Qi, X; Wan, Y; Wang, K; Xie, D; Xie, J; Yang, S, 2015) |
| "Glioma is a common malignant brain tumor originating in the central nervous system." | ( Fan, Y; Lv, S; Wu, M; Xiao, B; Ye, M; Zhu, X, 2016) |
| "Gliomas are the most frequent type of primary brain tumor in adults." | ( Chaudhary, H; Kataria, H; Kaur, G; Kumar, S, 2016) |
| "Glioma is a type of primary malignant tumor of the central nervous system in humans." | ( Chen, M; Hui, H; Jin, B; Ma, P; Pei, S; Shen, F; Wang, Z; Zhou, W; Zhou, X, 2015) |
| "Gliomas are aggressive tumors of the central nervous system that rely on production of growth factors for tumor progression." | ( Jiang, H; Liu, H; Mao, P; Wang, M; Xie, C; Xie, W, 2015) |
| "Malignant glioma is among the most challenging of all cancers to treat successfully." | ( Chen, T; Lin, L; Shen, H; Su, T; Yang, Z; Yuan, B, 2015) |
| "Glioma is one of the most common primary tumors of the central nervous system in adults." | ( Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY, 2015) |
| "Gliomas are the most common primary brain tumors." | ( Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L, 2015) |
| "Malignant glioma is the aggressive tumor in the brain and is characterized by high morbidity, high mortality." | ( Bao, J; Du, C; Jiang, Y; Liu, C; Tong, Q; Wang, J; Zhang, Q, 2015) |
| "The treatment of glioma is one of the most challenging tasks in clinic." | ( Chai, Z; Gao, J; Lu, W; Ran, D; Wei, X; Xie, C; Ying, M; Zhan, C; Zheng, P, 2015) |
| "Glioma is the most common primary brain tumor in the central nervous system (CNS) with high morbidity and mortality in adults." | ( Bi, Y; Gao, D; Hou, X; Li, C; Liu, H; Liu, Y; Liu, Z; Peng, F; Shen, C; Shi, C; Wang, K; Wang, X; Wu, J; Zhang, J; Zhao, B; Zhao, S; Zheng, Z; Zhong, C; Zou, H, 2016) |
| "Gliomas are the most common and the most malignant brain tumors, accouting for 45-55% of all intracranial tumors." | ( Cui, H; Matthiesen, R; Mu, Y; Su, X; Sun, W; Xi, YG; Yu, L, 2016) |
| "Malignant gliomas are notoriously resistant to therapies that induce apoptosis, but are less resistant to therapies that induce autophagy." | ( Galadari, S; Pallichankandy, S; Rahman, A; Thayyullathil, F, 2015) |
| "Gliomas are often recognized as highly heterogeneous cancerous phenotype." | ( Balkhi, HM; Gul, T; Haq, E, 2016) |
| "Gliomas are the most common type among all central nervous system tumors." | ( Buchpiguel, CA; Carneiro, CG; de Oliveira, ÉA; Faintuch, BL; Faria, DP; Fonoff, ET; Garcez, AT; Martinez, RCR; Moro, AM; Pagano, RL; Targino, RC, 2016) |
| "Gliomas are among the most commonly diagnosed central nervous system tumors." | ( Winfield, LL; Yerokun, T, 2015) |
| "Glioma is among the most common human malignancies with poor prognosis." | ( Che, S; Liu, X; Wang, C; Wang, J; Yan, Z; Yao, W, 2016) |
| "Glioma is one of the most common primary intracranial tumors, and the prognosis is poor even though much treatment management is employed." | ( Ma, L; Qi, X; Wan, Y; Wang, K; Xie, D; Xie, J; Yang, S, 2016) |
| "Malignant gliomas are tumors with a very unfavorable prognosis." | ( Kramm, CM; Kühnöl, CD; Staege, MS, 2016) |
| "Glioma is the most common malignant primary brain tumour with male preponderance and poor prognosis." | ( Dambach, H; Faustmann, PM; Förster, E; Moinfar, Z; Prochnow, N; Schoenebeck, B, 2016) |
| "Gliomas are among the most lethal primary brain tumors found in humans." | ( Chen, A; Chen, W; He, Y; Huang, B; Li, X; Wang, J; Zhang, C; Zhang, X, 2016) |
| "Gliomas are the most common primary tumors involving the central nervous system." | ( Andratschke, N; Brown, M; Gulden-Sala, W; Roth, P; Stupp, R; Weller, M, 2016) |
| "Malignant brain glioma is the most lethal and aggressive type of cancer." | ( Cheng, L; Jiang, Y; Li, XT; Meng, XS; Tang, W; Wang, XM; Wang, YH, 2016) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| "Diffuse gliomas are poorly immunogenic, fatal brain tumors." | ( Amankulor, N; Chan, T; Chang, Y; Choi, J; Deibert, C; Engh, J; Grandi, P; Kim, WJ; Kohanbash, G; Lotze, M; Okada, H; Park, Y; Pomerantz, A; Rao, A; Sette, P; Zhang, X, 2016) |
| "Glioma is the most common type of the primary CNS tumor." | ( Cui, Y; Li, FY; Li, HX; Shi, WQ; Wang, JZ; Xu, YJ; Zeng, QS, 2016) |
| "Malignant glioma is one of the most common intracranial tumor with a dismal prognosis." | ( Gu, N; Huang, Z; Jin, H; Lin, J; Liu, P; Ma, J; Wen, L; Wu, H; Zhao, P, 2016) |
| "Glioma is one of the most common malignant brain tumors." | ( Bai, Y; Dong, J; Du, Z; Guo, G; Hu, X; Huang, X; Jia, J; Lian, S; Ma, N; Shi, R; Song, B; Wang, M; Yang, B; Zhang, Y, 2016) |
| "Malignant gliomas are difficult to treat in clinical practice." | ( Chen, RM; Lin, CJ; Lin, YL; Luh, F; Yen, Y, 2016) |
| "Gliomas are the most common and lethal type of primary malignant brain tumor." | ( Fu, C; He, L; Li, M; Li, X; Peng, Y; Wang, M; Yin, Y; Zhang, LM, 2016) |
| "Gliomas are highly malignant tumors, the most common of which are astrocytomas." | ( Duan, ZL; Geng, F; Gu, X; Liang, ZP; Lu, GF; Wu, JL, 2016) |
| "Malignant gliomas are rarely curable malignant tumors in the central nervous system." | ( Guo, Z; Wang, X, 2015) |
| "Glioma is the most common form of primary malignant brain tumor in adults, with approximately 4 cases per 100 000 people each year." | ( Affleck, VS; Joshi, AR; Lin, H; Maxwell, R; Patel, S; Stoll, EA; Turnbull, DM; Wilson, I, 2017) |
| "Gliomas are central nervous system tumors that primarily occur in the brain and arise from glial cells." | ( Boyd, NH; Hjelmeland, AB; Tran, AN; Walker, K, 2017) |
| "Malignant gliomas are aggressive and life-threatening tumours that still show a poor prognosis: the current therapeutic approach based on surgical resection and chemotherapy combined with radiotherapy does not provide a satisfactory chance of long-term survival to patients." | ( Mucignat-Caretta, C; Pavan, V; Pezzani, R; Redaelli, M; Ribaudo, G; Zagotto, G; Zorzan, M, 2017) |
| "Malignant gliomas are locally invasive tumors that offer a poor prognosis." | ( Ma, R; Watts, C, 2016) |
| "Malignant gliomas are aggressive brain tumours with very poor prognosis." | ( Barba, L; Bassoy, EY; Boehler, M; Calvo Tardón, M; Dietrich, PY; Jueliger, S; Marinari, E; Martinvalet, D; Pellegatta, S; Riccadonna, C; Taverna, P; Vuillefroy de Silly, R; Walker, PR; Yacoub Maroun, C, 2016) |
| "Neuroglioma is a complex neuroglial tumor involving dysregulation of many biological pathways at multiple levels." | ( Feng, FQ; Ji, PG; Li, BF; Liu, JH; Lou, M; Wang, L; Yang, C; Zhang, LN, 2016) |
| "Glioma is the most frequent primary tumor, and the treatment efficiency is unsatisfactory for the obstacle of the blood brain barrier (BBB), the multidrug resistance (MDR) and the properties of cancer cell invasion and vasculogenic mimicry (VM) formation." | ( Cheng, L; Gu, LY; Jiang, Y; Li, XT; Liu, S; Song, XL; Wang, X; Xiao, Y, 2017) |
| "Gliomas are the most common primary intracranial malignant tumors in adults." | ( Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G, 2016) |
| "Glioma is still difficult to treat because of its high malignancy, high recurrence rate, and high resistance to anticancer drugs." | ( Dai, X; Lan, Q; Ma, C; Xu, T, 2016) |
| "Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited." | ( Chong, Y; Gao, S; Liu, H; Liu, N; Liu, X; Niu, M; Qi, Z; Tu, Y; Yao, Y; Yu, R; Yue, C, 2016) |
| "Human glioma is the most common type of primary brain tumor and one of the most invasive and aggressive tumors, which, even with treatments including surgery, radiotherapy and chemotherapy, often relapses and exhibits resistance to conventional treatment methods." | ( Liu, D; Tang, JT; Tang, T; Tang, Y; Wu, DH; Xiang, GH; Xie, L; Zhang, YR; Zhao, LY; Zhou, S, 2016) |
| "Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults." | ( Ali, SM; Brennan, T; Chmielecki, J; Elvin, JA; Hamilton, R; Meletath, SK; Melguizo-Gavilanes, I; Miller, VA; Palma, N; Pavlick, D; Rajaram, V; Ross, JS; Snipes, G; Stephens, PJ, 2016) |
| "Gliomas are the most common primary brain tumors in adults and invariably carry a poor prognosis." | ( Blondin, N; Chaudhry, A; Connelly, J; Hormigo, A; Hu, J; Mohilie, N, 2016) |
| "Malignant gliomas are highly dependent on the isoprenoid pathway for the synthesis of lipid moieties critical for cell proliferation." | ( Abate, M; Bifulco, M; Catapano, G; Ciaglia, E; Franceschelli, S; Gazzerro, P; Laezza, C; Pisanti, S; Seneca, V; Torelli, G; Vitale, M, 2017) |
| "Glioma is one of the most common malignant central nervous system tumors in humans." | ( Bao, J; Du, C; Jiang, Y; Liu, C; Tong, Q; Wang, J; Zhang, Q, 2017) |
| "First, glioma is known to have increased resistant to radiation due to its intra-tumoral hypoxia." | ( Cai, Y; Li, B; Liu, H; Liu, Y; Lu, J; Mao, H; Xie, Y; Yu, R; Zhang, L; Zhang, Y, 2017) |
| "Glioma is one of the most common types of brain tumors." | ( Li, F; Li, H; Shi, W; Xu, Y; Yi, C; Zeng, Q, 2017) |
| "Gliomas are primary brain tumors, originating from the glial cells in the brain." | ( Barkhof, F; de Witt Hamer, PC; Derks, J; Dirkson, AR; Douw, L; Geurts, JJ; Hulst, HE; Pouwels, PJ; Reijneveld, JC; van Geest, Q, 2017) |
| "Malignant gliomas are associated with a high mortality rate." | ( Gao, S; Liu, H; Liu, N; Liu, X; Niu, M; Qi, Z; Shi, Q; Tu, Y; Xie, P; Yu, R; Yue, C, 2017) |
| "Malignant glioma is the most aggressive brain tumor." | ( Chen, JT; Chen, RM; Cheng, BC; Chio, CC; Liu, SH; Yang, ST, 2017) |
| "Malignant glioma is a formidable disease that commonly leads to death, mainly due to the invasion of tumor cells into neighboring tissues." | ( Christian, L; Li, J; Mei, S; Niu, H; Perfetto, M; Ping, Z; Qu, J; Shi, Y; Wei, S; Yang, X; Zhang, Q, 2017) |
| "Diffuse low-grade gliomas are rare primitive cerebral tumours of adults." | ( Ben Abdallah, M; Blonski, M; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S, 2016) |
| "Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ)." | ( Asad, AS; Candolfi, M; Castro, MG; Chandran, M; Koschmann, C; Lowenstein, PR; Mineharu, Y; Shah, D; Yadav, VN, 2017) |
| "Glioma is the most frequent primary central nervous system tumor." | ( Chen, FR; Chen, ZP; Feng, HB; Guo, CC; Jiang, HR; Mei, X; Qu, Y; Sai, K; Wang, J; Yang, QY; Zhang, ZP; Zhao, YY, 2017) |
| "Hypoxia in gliomas is associated with tumor resistance to radio- and chemotherapy." | ( Barré, L; Bekaert, L; Bernaudin, M; Bordji, K; Branger, P; Collet, S; Constans, JM; Emery, E; Guillamo, JS; Lechapt-Zalcman, E; Levallet, G; Manrique, A; Petit, E; Ponte, K; Valable, S, 2017) |
| "High-grade glioma is a very aggressive and infiltrative tumor in which complete resection is a chance for a better outcome." | ( Borrás Moreno, JM; García Vicente, AM; Jiménez Aragón, F; Jiménez Londoño, GA; Villena Martín, M, 2017) |
| "Malignant glioma is the most common and aggressive form of brain tumor with poor prognosis of survival." | ( Li, K; Liu, JW; Wang, HT; Xiong, ZQ; Zheng, J; Zhu, ZC, 2017) |
| "Glioma is the most common primary brain tumor and has an undesirable prognosis due to the blood-brain barrier (BBB) and drug resistance." | ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2017) |
| "Gliomas are the most common and primary tumors of the central nervous system in adults." | ( Guan, Y; Qiu, B; Wang, Y; Wu, A; Zhang, D; Zhang, L, 2017) |
| "Glioma is the most common primary tumor of the central nervous system, and accounted for about 70% of primary tumors." | ( Hao, X; Xin, S; Yang, C; Yu, F, 2017) |
| "miltiorrhiza)." | ( Cao, Y; Gao, C; Huang, B, 2017) |
| "Glioma is one of the most lethal malignancies, and increasing reports revealed that microRNAs (miRNAs), a class of small non-coding RNAs, play a critical role in the development and pathology of human gliomas." | ( Jiang, Y; Jin, C; Li, M; Ouyang, Y; Tan, Z, 2017) |
| "Gliomas are a malignant tumor group whose patients have survival rates around 12 months." | ( Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI, 2017) |
| "High-grade gliomas are aggressive and intensely glycolytic tumors." | ( Castilho, RF; Figueira, TR; Ignarro, RS; Rodrigues-Silva, E; Rogério, F; Ruas, JS; Siqueira-Santos, ES, 2017) |
| "Glioma is the most common primary malignant tumor of the central nervous system." | ( Bai, X; Huo, L; Wang, M; Wang, Y, 2017) |
| "Glioma is the most prevalent type of adult primary brain tumor and chemotherapy of glioma was limited by drug-resistance." | ( Cheng, Y; Dai, C; Zhang, J, 2017) |
| "Gliomas are the most common brain tumors of the center nervous system." | ( Cao, Y; Chen, X; Gao, Y; Hao, B; Li, D, 2017) |
| "Glioma is the most common and lethal central nervous system tumors." | ( Chen, Y; Gao, F; Hou, J; Jiang, R; Kang, L; Li, Y; Liu, H; Liu, X; Yang, M; Yi, Y, 2017) |
| "Malignant brain glioma is the most common and aggressive type of primary intracranial neoplasm." | ( Chen, GR; Cheng, L; Gu, LY; Ju, RJ; Li, XT; Liu, S; Song, XL; Wang, X; Xiao, Y; Zhang, SM, 2017) |
| "Malignant glioma is the most fatal of astrocytic lineage tumors despite therapeutic advances." | ( Bhattacharya, D; Chaudhuri, S; Datta, A; Faruk Sk Md, O; Ghosh, TK; Hazra, I; Mondal, S; Ronsard, L; Singh, MK, 2018) |
| "Glioma is the most common primary malignant brain tumour and the effect of chemotherapy is hampered by low permeability across the blood-brain-barrier (BBB)." | ( Fei, W; Han, S; Huang, A; Li, F; Li, J; Lu, Y; Shi, X; Sun, Y; Xu, X; Zheng, H, 2018) |
| "Fluorescence in NE gliomas is highly predictive of diagnostic tumor tissue and regions of higher cell density and proliferative activity." | ( Bowden, SG; Bruce, JN; Canoll, P; Chang, PD; D'Amico, RS; Englander, ZK; Gill, BJA; Grinband, J; McKhann, GM; Neira, JA; Samanamud, J; Sheth, SA; Sisti, MB; Ung, TH; Zanazzi, G, 2018) |
| "Glioma is stemmed from the glial cells in the brain, which is accounted for about 45% of all intracranial tumors." | ( Chen, F; Chen, J; Du, D; Mi, Y; Zhang, C, 2017) |
| "Malignant glioma is a clinically formidable disease." | ( Li, J; Mei, S; Niu, H; Yang, X, 2017) |
| "Glioma is one of the lethal malignancies with poor prognosis." | ( Chen, PN; Hsieh, PL; Liao, YW; Lu, KH; Ouyang, WC; Yu, CC, 2017) |
| "Glioma is one of the most common primary brain tumors in adults with a high mortality rate and relapse rate." | ( Huang, T; Li, B; Liu, N; Shen, W; Wang, F, 2017) |
| "Gliomas are devastating cancers and their positive treatment outcome using Temozolomide (TMZ) is limited due to its short plasma half-life, systemic toxicity and limited access through the blood-brain barrier (BBB)." | ( Ahsan, SM; Kondapi, AK; Kumar, JM; Kumari, S; Rao, NM, 2017) |
| "Malignant gliomas are highly invasive, difficult to treat, and account for 2% of cancer deaths worldwide." | ( Chen, Y; Eubanks, JH; Fisher, CJ; Foltz, W; Lilge, L; Niu, C; Sidorova-Darmos, E, 2017) |
| "Human neuroglioma is one of the most common malignant intracranial tumors in neurosurgery, and accounts for more than 50% of all brain cancer cases." | ( Meng, X; Song, F; Wang, Y; Wang, Z; Yu, J; Yu, X; Zhang, H, 2017) |
| "Glioma is the most common type of primary brain tumor and has an undesirable prognosis." | ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2018) |
| "Human gliomas are related to high rates of morbidity and mortality." | ( Bian, E; Guo, Z; Li, G; Ma, CC; Wan, J; Zhao, B, 2017) |
| "Glioma is among the most formidable brain cancers due to location in the brain." | ( Chai, Z; Gao, B; Guan, J; Hu, X; Liu, J; Liu, X; Lu, W; Qian, J; Yang, Y; Zhan, C; Zhang, Z, 2017) |
| "Glioma is one of the most lethal brain malignancies with unknown etiologies." | ( Cao, Y; Fang, X; Gao, P; Ji, M; Liu, Y; Sun, A; Yu, Z; Zhang, Y; Zhao, L, 2017) |
| "Glioma is the most common form of malignant brain cancer with high mortality rate in human." | ( Chen, SL; Ding, XM; Feng, FQ; Ji, HM; Jia, L; Ma, JH; Ren, JR; Ren, SH; Zhen, ZG; Zou, P, 2017) |
| "Malignant glioma is one of the most untreatable cancers because of the formidable blood-brain barrier (BBB), through which few therapeutics can penetrate and reach the tumors." | ( Chen, Y; Huang, Y; Jin, H; Li, D; Wang, J; Wu, A; Xu, F; Zhang, M, 2017) |
| "Malignant glioma is the most common primary brain tumor in adults and has a poor prognosis." | ( Hua, L; Liu, X; Niu, M; Shan, QQ; Tu, Y; Xie, P; Yu, R; Yue, C; Zhou, T, 2017) |
| "High-grade gliomas are primary brain tumors that have shown increasing incidence and unfavorable outcomes." | ( Duhamel, A; Lejeune, JP; Leroux, B; Leroy, HA; Mordon, S; Reyns, N; Vermandel, M, 2018) |
| "Malignant gliomas are a group of aggressive neoplasms among human cancers." | ( An, TT; Chen, YD; Dong, TX; Liu, PF; Xu, YT; Yang, XH; Zhang, W; Zhang, Y, 2017) |
| "Glioma is one of the most common malignant cancers of the central nervous system (CNS)." | ( Kargar, S; Khoee, S; Khoei, S; Mahdavi, SR; Shirvalilou, S, 2018) |
| "Glioma is the most malignant type of primary central nervous system tumors, and has an extremely poor prognosis." | ( Chang, GE; Che, L; Cheong, E; Ha, Y; Kang, SG; Kim, JB; Kim, Y; Oh, J, 2017) |
| "Gliomas are the most common type of tumor in the brain." | ( Beyer, T; Grahovac, M; Hacker, M; Kiesel, B; Mitterhauser, M; Papp, L; Pötsch, N; Preusser, M; Schmidbauer, V; Traub-Weidinger, T; Wadsak, W; Woehrer, A, 2018) |
| "Glioma is the most devastating cancer in the brain and has a poor prognosis in adults." | ( Gao, M; Hou, X; Liu, H; Liu, Y; Peng, F; Shu, M; Wang, K; Wang, X; Xue, L; Ye, J; Zhao, B; Zhao, S; Zhao, W; Zhong, C, 2017) |
| "Glioma is a heterogeneous, highly complicated central nervous system (CNS) tumor with uncertain mechanism of initiation and progression, resulting in an unfavorable outcome." | ( Christofides, A; Drekolias, D; Gargalionis, AN; Kosmopoulos, M; Piperi, C; Zavras, PD, 2018) |
| "Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance." | ( Hu, J; Liu, JH; Wang, GB; Xue, K, 2017) |
| "Malignant glioma is the most common primary malignant brain tumor that displays high vascularity, making vascular endothelial growth factor receptors become promising targets." | ( Jiang, X; Li, C; Liang, L; Liu, L; Lu, P; Qiao, Y; Wang, L; Xia, Y; Yang, T, 2017) |
| "Gliomas are the most common primary tumors in central nervous system." | ( Chen, DG; Huang, C; Li, GH; Li, Q; Lv, SQ; Tang, J; Wang, DL; Zhou, P; Zhu, B; Zhu, H, 2017) |
| "Gliomas are a highly heterogeneous tumor, refractory to treatment and the most frequently diagnosed primary brain tumor." | ( D'Agostino, D; Egan, KM; Koutnik, AP; Kumar, NB; Poff, A; Sahebjam, S, 2019) |
| "Malignant gliomas are highly lethal cancers worldwide as tumor cells infiltrate to healthy brain tissue invariably." | ( Dai, B; Guan, F; Hu, Z; Huang, H; Mao, B; Su, H; Xiao, Z; Zhu, G, 2018) |
| "Gliomas are the most common type of primary, malignant brain tumor and significantly impact patients, who have a median survival of ~1 year depending on mutational background." | ( Burrell, LD; Gillespie, DL; Horn, KP; Jensen, RL; Karsy, M; Yap, JT, 2018) |
| "Glioma is the most common malignant tumor in the central nervous system." | ( Du, Z; Jin, T; Li, E; Liu, M; Wu, B; Xu, H; Xu, K; Xu, L; Xu, Z, 2017) |
| "Malignant glioma is a highly infiltrative malignancy that causes variable disruptions to the structure and function of the cerebrovasculature." | ( Bowden, SG; Bruce, JN; Canoll, P; Chang, PD; Englander, ZK; Gill, BJA; Grinband, J; Horenstein, CI; Lignelli, A; Samanamud, J; Zanazzi, G, 2018) |
| "Malignant gliomas are the most common primary brain tumors and have devastatingly high mortality rates." | ( Cohen, RJ; Mehta, MP, 2018) |
| "Oligodendrogliomas are therapy-responsive tumors, which have better prognosis compared to their astrocytic counterparts." | ( Drappatz, J; Lieberman, F, 2018) |
| "Glioma is one of the most malignant forms of brain tumor, and has been of persistent concern due to its high recurrence and mortality rates, and limited therapeutic options." | ( Cheng, SX; Li, J; Sun, HT; Tu, Y; Xu, HX; Xu, RC; Xu, ZW; Yang, XS; Yi, TL; Yu, ZQ; Zhang, S; Zhang, WB, 2018) |
| "Adult brainstem gliomas are difficult to classify based on radiologic and histologic features." | ( Cai, C; Daoud, EV; Foong, C; Hatanpaa, KJ; Martin, GR; Mickey, BE; Oberle, RJ; Pan, E; Raisanen, JM; Rajaram, V; White, CL, 2018) |
| "Glioma is the most common intracranial malignant tumors, accounting for about 40% of intracranial tumors." | ( Jiang, Y; Tan, Z; Zhao, J, 2018) |
| "Gliomas are the most frequent brain tumors in the adult population and unfortunately the adjuvant therapies are not effective." | ( Martínez-Martos, JM; Ramírez-Expósito, MJ, 2019) |
| "Gliomas are the most common malignant brain tumor, but treatment is limited by the blood-brain barrier (BBB), especially for chemotherapeutic drugs." | ( Hua, H; Jiang, Y; Liu, S; Lu, X; Meng, Q; Mu, H; Sun, K; Wan, Z; Wang, A; Wang, Y; Zhang, X; Zhang, Y, 2018) |
| "Malignant glioma is an aggressive type of brain tumor with poor prognosis and mostly incurable." | ( Hu, D; Li, M; Lin, K; Liu, P; Ma, Y; Zhang, L; Zhou, G, 2018) |
| "Malignant glioma is one of the most challenging central nervous system diseases to treat and has high rates of recurrence and mortality." | ( Lan, YL; Lou, JC; Ma, XC; Wang, H; Wang, X; Xing, JS; Yu, ZL; Zhang, B; Zou, S, 2018) |
| "Glioma is the most aggressive and lethal brain tumor in humans, it comprises about 30 per cent of all brain tumors and central nervous system tumors." | ( Fu, A; Fu, C; Yu, Y; Zhao, M, 2018) |
| "Glioma is a highly challenging human malignancy as drugs typically exhibit a low blood-brain barrier (BBB) permeability as well as poor glioma selectivity and penetration." | ( Cheng, R; Deng, C; Feijen, J; Jiang, Y; Meng, F; Zhang, J; Zhong, Z; Zhu, Y, 2018) |
| "Glioma is a heterogeneous, invasive primary brain tumor with a wide range of patient survival and a lack of reliable prognostic biomarkers." | ( Cao, J; Chen, Y; Ding, Y; Gao, H; Huang, H; Lei, T; Li, G; Shen, J; Sun, Y; Xu, W; Zhan, Z; Zhou, G, 2018) |
| "Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma." | ( Bettegowda, C; Lim, M; Weller, M; Xia, Y, 2018) |
| "Malignant glioma are linked to a high mortality rate." | ( Chen, G; Han, C; Sun, XK; Wang, F; Xu, ZF; Zhang, YD, 2018) |
| "Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments." | ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018) |
| "Glioma is the most fatal primary brain glioma in central nervous system mainly attributed to its high invasion." | ( Bi, LL; Gao, YM; Qiao, H; Wang, YB, 2018) |
| "Gliomas are a lethal class of brain cancer, with a median survival below 15 months in spite of therapeutic advances." | ( Cao, L; Li, J; Song, J; Song, L; Tan, Z; Wu, G; Wu, W; Zhang, W; Zhou, Y; Zhu, J, 2018) |
| "Glioma is a wide category of brain tumor originates from glial cells." | ( Mahalingam, K; Patil, V, 2018) |
| "Glioma is a type of tumor that starts in the glial cells of brain and spine." | ( Duan, J; Luo, R; Tang, X; Wang, Y; Yang, B; Zhao, L, 2018) |
| "Malignant glioma is the most common type of brain tumor with poor clinical outcome and survival." | ( Chao, F; Feng, T; Haijing, W; Hong, J; Hongli, L; Hui, Z; Linfeng, Y; Liugeng, W; Xiaohua, Z; Yingli, N; Zhaohui, W, 2018) |
| "Glioma is the most frequent primary brain tumour of the central nervous system." | ( Chen, W; Chen, Y; Liu, H; Liu, J; Liu, X; Sheng, Z; Yan, F; Yeh, CK; Zheng, H; Zhou, M, 2018) |
| "Glioma is the most common and lethal primary brain tumor." | ( Chen, MF; Cheng, CY; Wang, TC; Yang, WH, 2018) |
| "Highly malignant gliomas are characterized by pronounced intra‑ and intertumoral heterogeneity." | ( Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M, 2018) |
| "Gliomas are highly malignant brain tumours characterised by extensive areas of poor perfusion which subsequently leads to hypoxia and reduced survival." | ( Cruickshank, G; Eales, KL; Tennant, DA; Tucker, JHR; Wilkinson, EA, 2018) |
| "Glioma is the most prevalent malignant brain tumor." | ( Cui, J; Hong, X; Jia, H; Li, Q; Li, R; Li, W; Zou, Z, 2018) |
| "Glioma is the most common and malignant form of primary brain tumour, and is characterised by high proliferation and extensive invasion and neurological destruction." | ( Chen, Y; Cui, H; Fu, G; Hu, R; Li, C; Pan, G; Shen, L; Zhang, K; Zhu, S, 2018) |
| "Malignant gliomas are aggressive primary neoplasms that originate in the glial cells of the brain or the spine with notable resistance to standard treatment options." | ( Bu, XY; Gao, YS; Han, SY; Hu, S; Qu, MQ; Wang, BQ; Wang, JY; Yan, ZY; Yang, B; Yang, HC, 2019) |
| "Malignant glioma is a severe type of brain tumor with a grim prognosis." | ( Chen, XB; Huo, JF, 2019) |
| "Gliomas are one of the most common types of primary brain tumors." | ( Baidya, A; He, Y; Li, YS; Lu, ST; Mei, H; Wu, B; Xu, D, 2018) |
| "Glioma is a primary brain tumor with high frequency and dismal prognosis." | ( Hao, F; Liu, B; Qi, C; Zhao, S; Zhao, X; Zhao, Z, 2019) |
| "Given that gliomas are derived from mutations in glial precursor cells, a considerable number of them strongly react with glial precursor cell‑specific markers." | ( Baek, D; Ha, Y; Kim, Y; Oh, J, 2019) |
| "Malignant glioma is a lethal brain tumor with a low survival rate and poor prognosis." | ( Lan, Q; Mao, J; Shao, N; Wang, R; Xue, L; Zhi, F, 2019) |
| "Glioma is the most common intracranial primary brain tumor." | ( Aarseth, JH; Gilhus, NE; Johannesen, TB; Knudsen-Baas, KM; Myklebust, TÅ; Owe, JF; Storstein, AM, 2018) |
| "Gliomas are lethal and aggressive form of brain tumors with resistance to conventional radiation and cytotoxic chemotherapies; inviting continuous efforts for drug discovery and drug delivery." | ( Anand, P; Gandhi, M; Jadhav, M; Padwad, Y; Purohit, R; Rawat, K; Shard, A; Sinha, AK, 2019) |
| "The prognosis of glioma is dismal, and almost all patients relapsed." | ( Alongi, F; Amelio, D; Borzillo, V; Ciammella, P; Clerici, E; di Monale, MB; Draghini, L; Fariselli, L; Ferrarese, F; Fiorentino, A; Galaverni, M; Krengli, M; Livi, L; Magrini, S; Maranzano, E; Masini, L; Minniti, G; Muto, P; Navarria, P; Pasqualetti, F; Pinzi, V; Scartoni, D; Scoccianti, S; Scorsetti, M; Tomatis, S, 2019) |
| "Malignant glioma is the most common type of brain cancer with poor prognosis." | ( Gagat, M; Grzanka, D; Hałas-Wiśniewska, M; Izdebska, M; Klimaszewska-Wiśniewska, A; Zielińska, W, 2019) |
| "Glioma is the most common brain malignancy." | ( Fedulov, A; Karlsson, I; Lokot, I; Pejler, G; Veevnik, D; Yurkshtovich, N; Yurkshtovich, T, 2019) |
| "Glioma is a fatal disease with limited treatment options and very short survival." | ( Chu, X; Cui, L; Feng, Y; Fu, S; Gao, C; Gong, W; Li, Z; Liang, M; Liu, Q; Wang, Y; Xie, X; Yang, C; Yang, M; Yang, Y, 2019) |
| "Glioma is a deadly form of brain cancer." | ( Bi, YE; Dong, S; Fu, Y; Hao, F; Lee, RJ; Sun, Y; Teng, L; Xie, J; Yuan, BO; Zhao, Y, 2019) |
| "Malignant glioma is one of the most common and severe brain diseases, which is extremely hard to treat due to the presence of the blood-brain barrier (BBB)." | ( Geng, X; Liu, Q; Sun, Y; Wang, H; Wang, P; Wang, X; Zhang, K, 2019) |
| "The treatment of glioma is a great challenge because of the existence of the blood-brain barrier (BBB)." | ( Chen, Y; Fu, Q; Guo, L; Wu, Y; Xiao, W; Yang, Y; Yang, Z; Yue, Q; Zhao, Y, 2019) |
| "Human glioma is the most common type of primary brain tumor." | ( Liu, J; Lv, H; Ma, R; Shao, C; Zhang, G; Zheng, G, 2018) |
| "Risk of high grade gliomas is lower in young females and its incidence enhances after menopause suggesting likely protective roles of female hormones." | ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Glioma is the most common primary cancer in central nervous system, especially in brain." | ( Bashllari, R; Cimino, F; Costa, G; Ferlazzo, G; Fratantonio, D; Molonia, MS; Muscarà, C; Saija, A; Speciale, A, 2019) |
| "Malignant glioma is the most common and deadliest brain cancer due to the obstacle from indistinct tumor margins for surgical excision and blood brain barrier (BBB) for chemotherapy." | ( Huang, H; Li, Y; Song, N; Sun, N; Xing, Y; Zhao, J; Zhao, L; Zhu, J, 2019) |
| "Glioma is one of the most epidemic and obstinate types of cancer in the central nervous system (CNS) with poor survival rate." | ( Chen, WS; Hong, L; Li, JJ; Wang, F, 2019) |
| "Diffuse gliomas are incurable malignancies, which undergo inevitable progression and are associated with seizure in 50-90% of cases." | ( Davis, KA; Desmond, P; Drummond, K; Glarin, R; Hariharan, H; Kwan, P; Moffat, BA; Morokoff, A; Nanga, RPR; Neal, A; O'Brien, TJ; Reddy, R; Shinohara, RT; Stein, JM, 2019) |
| "Glioma is a commonly diagnosed brain tumor that shows high mortality rate." | ( Hu, D; Li, R; Luo, L; Ni, W; Wen, F; Xu, X; Zuo, P, 2019) |
| "Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma." | ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019) |
| "Glioma is a primary intracranial malignant tumor with poor prognosis." | ( Liu, G; Mao, J; Meng, X; Yang, Y; Zhao, C, 2019) |
| "Glioma is the most frequent form of malignant brain tumors." | ( Bi, YY; Cao, C; Chen, L; Duan, W; Feng, J; Han, L; Jin, Z; Li, C; Li, X; Liu, Y; Mao, Y; Wang, C; Xu, W; Yue, Q; Zhai, Y; Zhang, XY, 2019) |
| "Gliomas are incurable solid tumors with extremely high relapse rate and definite mortality." | ( Babu, PP; Narne, P; Pandey, V; Ranjan, N, 2019) |
| "Malignant glioma is the most common primary malignancy in the brain." | ( Gao, C; He, XF; Meng, ZX; Shen, J, 2020) |
| "Glioma is a common brain tumor with a high mortality rate." | ( Bai, X; Hu, M; Jia, L; Li, Y; Tan, X; Wang, Q; Yang, X; Zeng, X; Zhang, Z; Zhu, Y, 2019) |
| "Glioma is a highly aggressive and lethal brain tumor." | ( Fang, Z; Fu, J; Hua, L; Liu, H; Wang, G; Wang, Z; Ye, C; Yu, R; Zhao, L; Zhu, Y; Zhuang, T; Zong, Z, 2019) |
| "Malignant gliomas are the most common primary brain tumors." | ( Arnault, P; Benzakour, O; Coronas, V; Ginisty, A; Oliver, L; Vallette, F, 2019) |
| "Gliomas are tumors that originate from glial cells present in the brain and spinal cord." | ( DeCoster, MA; Kelly, KC; Savarraj, JP, 2019) |
| "Glioma is the most common form of malignant brain cancer with high mortality rate in human." | ( Guo, Z; Guozhang, H; Li, Z; Liu, N; Wang, H, 2019) |
| "First, gliomas are deemed exceedingly radio-resistant tumors, owing to efficient DNA double-strand break repair." | ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Malignant glioma is the most aggressive primary brain tumor and has a poor survival rate." | ( Ge, H; Jiang, Y; Yang, Z; Yin, H; Zhang, Y, 2019) |
| "Glioma is one of the most aggressive primary brain tumors and is incurable." | ( Abou-Elella, F; AbouAitah, K; Aboul-Enein, AM; Ahmed, ER; Higazy, IM; Lojkowski, W; Mousa, SA; Shahein, SA, 2019) |
| "Gliomas are the most common brain tumors in humans." | ( Jie, C; Yang, F; Yi, S; Zhang, G, 2019) |
| "Chordoid gliomas are extremely rare entities, which are generally considered occurring exclusively in the third ventricle." | ( Du, J; Fang, J; Li, G; Wang, S; Xu, Y; Yang, B; Yang, C, 2020) |
| "Glioma is one of the most refractory types of brain tumor." | ( Alfano, RR; Cheng, G; Liu, CH; Shi, L; Wang, K; Wu, B; Yu, X; Zhang, C; Zhang, L; Zhao, M; Zhou, Y; Zhu, K; Zong, R, 2019) |
| "High-grade gliomas are lethal brain cancers whose progression is robustly regulated by neuronal activity." | ( Agarwal, A; Arzt, M; Bergles, DE; Brang, D; Espenel, C; Geraghty, AC; Gillespie, SM; Hervey-Jumper, S; Malenka, RC; Monje, M; Morishita, W; Ni, L; Ponnuswami, A; Regev, A; Silverbush, D; Suvà, ML; Tam, LT; Taylor, KR; Venkatesh, HS; Vogel, H; Woo, PJ, 2019) |
| "Glioma is one of the most lethal malignancies and molecular regulators driving gliomagenesis are incompletely understood." | ( Dai, X; He, Q; Shao, Y; Tan, B; Wang, J; Weng, Q; Yang, B; Zhao, M, 2019) |
| "Glioma is the most aggressive and lethal brain tumor in humans." | ( Fu, A; Fu, C; Hou, Y; Li, J; Zhang, L; Zhao, Z; Zhou, W, 2019) |
| "Gliomas are the most dreaded primary brain tumour because of their dismal cure rates." | ( Chaudhary, R; Gaskill-Shipley, M; Ward, T; Woodhouse, C, 2019) |
| "Glioma is one of the most aggressive and common malignant brain tumors." | ( Dong, S; Lee, RJ; Teng, L; Wang, X; Yang, D; Zhang, H; Zhao, Y, 2019) |
| "Glioma is the most common primary malignant tumor in the central nervous system." | ( Guan, F; Hu, ZQ; Kang, Z; Lin, ZY; Mao, BB; Peng, WC; Wang, K; Wang, L; Zhang, BL; Zhang, JT, 2019) |
| "Glioma is the most common malignant tumor of the central nervous system (CNS)." | ( Chen, L; Chen, PR; Gao, Y; Li, C; Lin, J; Xu, N; Zeng, D; Zhang, W; Zhu, X, 2019) |
| "Malignant gliomas are rapidly progressive brain tumors with high mortality." | ( Ayinon, C; Balaj, L; Carter, BS; Charest, A; Delcuze, B; Ghiran, I; Hochberg, FH; Jones, PS; Lansbury, E; Mordecai, S; Small, JL; Tigges, J; Yekula, A, 2019) |
| "Glioma is the most aggressive primary brain tumor." | ( Bian, E; Ji, X; Tang, F; Wang, H; Yang, Z; Zhang, Y; Zhao, B, 2020) |
| "Glioma is the most common neoplasm of the central nervous system, with the highest mortality rate." | ( Faming, W; Hang, S; Hongyan, Z; Liudi, Y; Mengmeng, T; Younis, M, 2019) |
| "Glioma is a common brain malignancy for which new drug development is urgently needed because of radiotherapy and drug resistance." | ( Chen, T; Chen, Z; Liu, L; Liu, Y; Nie, Y; Ouyang, Q; Wei, S; Yin, W; Zeng, F, 2020) |
| "Glioma is one of the most common types of primary brain tumors." | ( Chen, C; Gao, A; Liang, H; Liu, J; Meng, J; Qu, F; Wang, H; Wang, Q; Wang, X; Yang, K; Zhao, N, 2019) |
| "Glioma is associated with high recurrence and poor survival, despite the success of tumor resection surgery." | ( Chang, JL; Cheng, HL; Lee, TS; Liao, MH; Shih, CC; Sung, CH; Tsuang, FY; Wu, CY; Yang, YW, 2021) |
| "High-grade gliomas are associated with poor prognosis." | ( Antti, H; Asklund, T; Bergenheim, AT; Bergström, P; Björkblom, B; Johansson, M; Jonsson, P; Tabatabaei, P, 2020) |
| "Glioma is one of the most common aggressive brain malignancies, but the treatment of glioma is still far from satisfying." | ( Fu, Y; Guo, C; Huang, S; Li, L; Lin, Q; Liu, W; Wang, L; Zhang, L; Zhang, Z, 2020) |
| "Gliomas are the most common, malignant, and lethal tumors in adults." | ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B; Zhang, Q; Zhou, N, 2020) |
| "Glioma is the prime cause of cancer allied mortality in adolescent people and it accounts about 80% of all malignant tumours." | ( Aladresi, AAM; Alharbi, SA; Aruni, W; Bolla, SR; Chinnathambi, A; Kumaran, S; Lakshmanan, H; Li, Z; Mohan, SK; Shair, OHM; Veeraraghavan, VP, 2020) |
| "Glioma is the most common type of primary brain tumor, and it has a high mortality rate." | ( Chen, D; Lee, TH; Wang, C; Wang, L; Wu, Y; Zhou, Y, 2020) |
| "Gliomas are molecularly complex neoplasms and require a multidisciplinary approach to treatment." | ( Brown, DA; Chaichana, KL; Navarro-Bonnet, J; Quinones-Hinojosa, A; Suarez-Meade, P, 2019) |
| "Gliomas are infiltrative brain tumors with a margin difficult to identify." | ( Alston, L; Brevet, PF; Frindel, C; Guyotat, J; Leclerc, P; Mahieu-Williame, L; Meyronet, D; Montcel, B; Ray, C; Rousseau, D, 2020) |
| "Gliomas are the most common neoplasm of the human central nervous system." | ( Fang, Y; Guo, K; Ou, S; Tang, H; Wang, F; Wu, T; Xu, J; Zhou, L, 2020) |
| "Glioma is a CNS tumor with few therapeutic options." | ( Antonangeli, F; D'Alessandro, G; Lauro, C; Limatola, C; Marrocco, F; Porzia, A; Santoni, A, 2020) |
| "Glioma is the most common type of malignant tumor of the nervous system, and aggressiveness and recurrence are major obstacles for treatment." | ( Chen, Y; Li, H; Li, N; Li, Y; Liu, M; Peng, H; Wang, H; Wang, J; Wang, N; Wang, Z; Zhang, Y, 2020) |
| "Glioma is a kind of lethal malignant tumor, and lacks efficient therapies." | ( Hu, Y; Lu, J; Luo, P; Qian, R; Yang, X; Zhang, Y, 2020) |
| "Glioma is the most common primary malignancy of the central nervous system and is associated with high mortality rates." | ( Binbin, Z; Chen, L; Hongmin, C; Jian, S; Minxue, L; Ronghua, T; Shiwen, G; Xiaoxuan, F, 2020) |
| "High grade gliomas are associated with poor prognosis and high mortality." | ( Black, KL; Chu, RM; Hu, JL; Mazer, MJ; Nuno, M; Phuphanich, S; Rudnick, JD; Sarmiento, JM; Uy, B; Wang, H; Wheeler, CJ; Yu, JS, 2020) |
| "Glioma is a brain tumour that is often diagnosed, and temozolomide (TMZ) is a common chemotherapeutic drug used in glioma." | ( Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y, 2020) |
| "High-grade gliomas are a type of malignant brain tumour." | ( , 2020) |
| "Diffuse gliomas are the most common primary brain tumors." | ( Li, D; Li, S; Liu, Y; Smith Callahan, LA; Xue, AZ, 2020) |
| "Gliomas are characterized by intratumoral histological heterogeneity, coexisting foci of low and high grade." | ( Borrás Moreno, JM; Cordero García, JM; García Vicente, AM; López Menéndez, C; Soriano Castrejón, A, 2020) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Glioma is one of the most common primary brain tumors, and it is responsible for most of the deaths caused by primary brain tumors." | ( Boeira, AJZ; Bona, NP; Cunico, W; de Vasconcelos, A; Drawanz, BB; Pedra, NS; Stefanello, FM, 2021) |
| "Glioma is a common cancer that affects people worldwide with high morbidity and mortality." | ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B, 2020) |
| "In adults, glioma is the most commonly occurring and invasive brain tumour." | ( Cao, Y; Kong, S; Li, X; Qi, Y; Shang, S, 2020) |
| "Gliomas are responsible for the majority of deaths from primary brain tumours." | ( Dong, X; Han, XC; Li, KH; Xing, QZ; Zhang, L; Zhang, YJ, 2020) |
| "Glioma is one of the most common primary malignant tumors of the central nervous system accounting for approximately 40% of all intracranial tumors." | ( Amankulor, NM; Begum, G; Castro, MG; Ding, D; Dodelson, J; Fiesler, VM; Gayden, J; Guan, X; Hasan, MN; Hu, B; Jia, W; Kohanbash, G; Luo, L; Sun, B; Sun, D, 2020) |
| "Gliomas are brain tumors with dismal prognoses." | ( Aikins, M; Castro, MG; Hassani Najafabadi, A; Kadiyala, P; Lowenstein, PR; Moon, JJ; Scheetz, L; Schwendeman, A; Son, S; Sun, X, 2020) |
| "Glioma is a highly aggressive and lethal brain tumor." | ( Kang, LY; Liu, WW; Tang, L; Wang, W; Wei, WT; Xia, R; Xu, W; Xue, R; Zheng, JW, 2020) |
| "Glioma is the most common brain malignancy and surgical resection is the primary option for patient with glioma." | ( Li, Z; Xing, F; Yuan, J; Zhang, W; Zhao, H, 2020) |
| "High grade-gliomas are highly invasive and prone to metastasis, leading to poor survival and prognosis." | ( Duan, X; Li, Q; Li, X; Li, Y; Shi, L; Wang, Y, 2020) |
| "Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas." | ( Bowden, C; Burris, H; Choe, S; Cloughesy, TF; Cote, GM; De La Fuente, MI; Ellingson, BM; Fan, B; Holdhoff, M; Huang, R; Janku, F; Jiang, L; Lu, M; Maher, E; Mellinghoff, IK; Pandya, SS; Steelman, L; Touat, M; Wen, PY; Yen, K; Young, RJ, 2020) |
| "Glioma is one of the most common malignant brain tumors and exhibits low resection rate and high recurrence risk." | ( Hao, L; Li, M; Liu, L; Ma, L; Song, S; Wang, G; Wang, L; Yu, C; Zhang, Z, 2020) |
| "Glioma is known as one of the most common primary intracranial tumors accounting for four-fifths of malignant brain tumors." | ( Asemi, Z; Behnam, M; Mirzaei, H; Pourattar, MA; Razavi, ZS; Tamtaji, OR, 2021) |
| "Gliomas are intrinsic brain tumours, which are classified by the World Health Organization (WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malignant subtype (WHO grade IV)." | ( Hofer, S; Hottinger, AF; Hundsberger, T; Läubli, H; Mamot, C; Pesce, G; Reinert, M; Roelcke, U; Roth, P; Schucht, P; Weller, M, 2020) |
| "Glioma is a leading cause of central nervous system malignant tumor-associated deaths in the world." | ( Li, R; Yang, W, 2020) |
| "Glioma is the most aggressive primary malignant brain tumor." | ( Han, Y; Jia, J; Liu, H; Lu, Y; Shen, J; Wang, L; Xu, H; Yu, R; Zhang, L; Zhao, Z, 2020) |
| "Gliomas are responsible for more than 60% of all primary brain tumors." | ( Barbosa, NG; Ferreira, GA; Izumi, C; Laure, HJ; Lopes, NP; Rosa, JC; Sousa, JPB; Thomé, CH, 2020) |
| "H3." | ( Bush, K; Carcaboso, AM; Cervantes, V; Chen, KY; Klein, RH; Knoepfler, PS; Lechpammer, M; Lewis, N; Naqvi, A, 2020) |
| "Gliomas are the most common primary malignant brain tumor in adults, but current treatment for glioblastoma multiforme (GBM) is insufficient." | ( Czarnecka-Herok, J; Juraszek, B; Nałęcz, KA, 2021) |
| "Glioma is one of the most destructive human tumours." | ( Li, X; Liu, L; Luo, Y; Shi, Y, 2020) |
| "Glioma is a highly malignant type of intracranial tumor with a poor prognosis resulting from traditional chemo-resistance with temozolomide (TMZ)." | ( Guan, W; Han, W; Wang, R; Yu, F; Zhi, F, 2021) |
| "Glioma is the most common primary intracranial tumor and is associated with very low survival rates." | ( Chai, R; Huang, L; Jiang, T; Li, G; Liu, Y; Wang, Y; Zhao, Z; Zhou, K, 2020) |
| "Glioma is a common type of malignant brain tumour with high mortality and relapse rate." | ( Chen, T; Lv, K; Yang, H; Zhu, X, 2020) |
| "Glioma is the most common type of brain cancer." | ( Ahmad, N; Meng, X; Sun, M; Yang, F; Yang, J; Yu, H; Zhao, R; Zhou, Y; Zhu, C; Zhuang, J, 2021) |
| "Glioma is the most common primary malignant tumour in the brain; temozolomide (TMZ) is the most prevalent chemotherapeutic drug currently used to combat this cancer." | ( Li, Y; Liu, Q; Long, W; Pan, Y; Qin, C; Su, J; Wang, J; Wang, X; Wu, C; Xiao, K; Xiao, Q, 2020) |
| "Malignant gliomas are the most lethal form of primary brain tumors." | ( Delinois, LJ; Griebenow, KH; Miller, J; Peón, H; Ramírez-Paz, J; Tinoco, AD; Villalobos-Santos, JC, 2020) |
| "Glioma is one of the most aggressive forms of brain tumor and is hallmarked by high rate of mortality, metastasis and drug resistance." | ( Feng, H; Hua, L; Huang, L; Zhang, X, 2020) |
| "Glioma is a malignant brain cancer that exhibits high invasive ability and poor prognosis." | ( Chen, Q; Gao, W; Ge, J; Liu, B; Liu, J; Tang, D; Yang, J; Zhao, J, 2020) |
| "Glioma is the most common primary intracranial tumor, in which glioblastoma (GBM) is the most malignant and lethal." | ( Hua, D; Jiang, Z; Luo, W; Shi, C; Sun, C; Tang, S; Wang, L; Wang, Q; Wang, W; Yu, H; Yu, L; Yu, S; Yu, Y; Zhang, D; Zhao, Q; Zhou, X, 2021) |
| "Glioma is the most malignant tumour of the human brain still lacking effective treatment modalities." | ( Bębenek, E; Boryczka, S; Dmoszyńska-Graniczka, M; Król, SK; Stepulak, A; Sławińska-Brych, A, 2020) |
| "Glioma is the commonest primary malignant brain tumour." | ( Kandasamy, R; Mat Zin, AA; Yunus, N; Zulkarnain, S; Zun, AB, 2020) |
| "Glioma is the primary malignant brain tumor with poor prognosis." | ( An, J; Dong, W; He, Y; Jia, X; Jia, Y; Liu, K; Ma, X; Pan, Y; Sheng, J; Wang, B; Wang, J; Wang, S; Wang, X; Wu, Y; Yu, D; Yu, W; Zhao, Y; Zhu, W, 2020) |
| "Gliomas are diagnosed and staged by conventional MRI." | ( Demetriou, E; Sotirios, B; Topriceanu, CC; Zakrzewska, Z, 2020) |
| "Malignant glioma is a fatal brain cancer." | ( Alam, MK; Lee, Y; Sidu, RK; Thakur, A; Yang, M; Zou, H, 2020) |
| "Gliomas are the most common primary brain tumors and often become apparent through symptomatic epileptic seizures." | ( Bräuer, AU; Brehme, H; Büttner, A; Einsle, A; Freiman, T; Henker, C; Kirschstein, T; Köhling, R; Lange, F; Linnebacher, M; Madadi, A; Müller, S; Rackow, S; Wolfart, J, 2021) |
| "Glioma is the most typical malignant brain tumor, and the chemotherapy to glioma is limited by poor permeability for crossing blood-brain-barrier (BBB) and insufficient availability." | ( Chen, X; Li, F; Piao, JG; Wei, Y; Wu, F; Zhang, K; Zhang, Y; Zheng, H; Zhu, J; Zhu, Z, 2021) |
| "Glioma is the most prevalent type of malignant brain tumor and is usually very aggressive." | ( Han, Y; Hua, L; Liu, H; Lu, J; Naveena, K; Wang, Z; Xu, H; Yu, R; Zhang, L; Zhao, G; Zhao, L; Zhao, Z, 2020) |
| "BACKGROUND Gliomas are commonly diagnosed tumors in the central nervous system that have an elevated mortality rate." | ( Jincao, C; Liu, Y; Peng, P; Tingbao, Z; Yaozu, Z; Zhao, H, 2020) |
| "Glioma is a prevalent primary brain tumor." | ( Jia, X; Li, W; Liu, Q; Ma, Q; Wang, X; Yan, P, 2021) |
| "Glioma is one of the most common primary intracranial tumor, but the current treatments of glioma are far from satisfying." | ( Hai, L; Liu, Q; Lu, R; Wang, S; Wu, Y; Yang, C; Zhou, L, 2021) |
| "Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy." | ( Chen, H; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Zhan, W; Zhang, Z, 2020) |
| "Malignant glioma is the most lethal form of brain cancer, and effective therapeutic modalities remain unavailable to date." | ( Bai, Z; Bian, D; Fang, Y; Shi, G; Zhang, Z, 2021) |
| "Gliomas are one of the most common types of brain tumors." | ( Ekici, S; Fleischer, CC; Neill, SG; Risk, BB; Shu, HK, 2020) |
| "Malignant gliomas are aggressive spinal cord tumors." | ( Che, L; Gwak, SJ; Ha, Y; Lee, M; Yun, Y, 2020) |
| "G34R/V gliomas are neuronal malignancies where interneuron progenitors are stalled in differentiation by G34R/V mutations and malignant gliogenesis is promoted by co-option of a potentially targetable pathway, PDGFRA signaling." | ( A, D; Albrecht, S; Andrade, AF; Bajic, A; Bandopadhayay, P; Bassenden, AV; Berghuis, AM; Beroukhim, R; Blanchette, M; Bognar, L; Brandner, S; Chen, CCL; Coutelier, M; Dali, R; De Jay, N; Deshmukh, S; Dubois, F; Ekert, PG; Ellezam, B; Faury, D; Filbin, MG; Garcia, BA; Garzia, L; Gayden, T; Hadjadj, D; Hansford, JR; Harutyunyan, AS; Hauser, P; Hébert, S; Jabado, N; Jawhar, W; Jessa, S; Jones, DTW; Juretic, N; Karamchandani, J; Khuong-Quang, DA; Kleinman, CL; Klekner, A; Korshunov, A; Kramm, C; Krskova, L; Ligon, KL; Lisi, V; Mack, SC; Maestro, N; Marchione, DM; Mikael, LG; Pathania, M; Pfister, SM; Russo, C; Salomoni, P; Sturm, D; Sumerauer, D; Suzuki, H; Taylor, MD; Vanova, K; Vicha, A; Virga, J; Weil, AG; Woodward, E; Zamecnik, J; Zapotocky, M; Zeinieh, M; Ziegler, DS, 2020) |
| "Glioma is known as the most common primary brain tumor occurring in adolescents and is considered as a lethal disease worldwide." | ( Asemi, Z; Dana, PM; Eslahi, M; Hallajzadeh, J; Mansournia, MA; Yousefi, B, 2021) |
| "Glioma is the most common malignant tumor of the nervous system, which accounts for more than 45% of central nervous system tumors and seriously threatens our health." | ( Chen, Y; Hao, K; Jiang, S; Li, K; Li, M; Li, Y; Wang, Q; Wang, Z; Wu, L; Zhang, W, 2020) |
| "Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q codeletion/TERT-promoter mutations or inactivating mutations in α-thalassemia/mental retardation syndrome X-linked (ATRX) and TP53." | ( Alghamri, MS; Appelman, H; Carney, SV; Castro, MG; Edwards, MB; Garcia-Fabiani, MB; Gauss, JC; Haase, S; Kadiyala, P; Kleer, CG; Li, D; Liu, Y; Lowenstein, PR; Moon, JJ; Núñez, FJ; Nunez, FM; Schwendeman, A; Sun, Y; Taher, A; Yu, M; Zhao, L, 2021) |
| "Glioma is a common primary malignant tumor that has a poor prognosis and often develops drug resistance." | ( Chen, X; Fu, M; Guan, X; Huangfu, M; Li, X; Liu, H; Qin, J; Wang, J; Wei, R; Yu, D, 2021) |
| "Glioma is the most common intracranial malignant tumour." | ( Li, X; Meng, Y, 2021) |
| "Gliomas are one of the most common types of primary brain tumors." | ( Baidya, A; Deng, K; Li, YS; Wu, B; Xu, D; Xu, HB, 2021) |
| "Canine glioma is a common brain tumor with poor prognosis despite surgery and/or radiation therapy." | ( Akiyoshi, H; Ichikawa, T; Inoue, M; Kamishina, H; Kurozumi, K; Matsumoto, Y; Nakamoto, Y; Noguchi, S, 2021) |
| "Malignant gliomas are highly invasive tumors." | ( Kuroiwa, T; Nonoguchi, N; Wanibuchi, M, 2021) |
| "Gliomas are one of the most aggressive brain tumors with a poor prognosis in the central nervous system." | ( Hacioglu, C; Kacar, S; Kanbak, G; Kar, F; Sahinturk, V, 2021) |
| "Gliomas are brain and spinal cord malignancies characterized by high malignancy, high recurrence and poor prognosis, the underlying mechanisms of which remain largely elusive." | ( Chao, M; Jia, L; Jiang, T; Jiang, Y; Liu, N; Sun, Z; Tu, Y; Wang, L; Xv, M, 2020) |
| "Angiocentric glioma is an indolent and rare low-grade glioma." | ( Antonelli, M; Aronica, E; Barba, C; Bertero, L; Buccoliero, AM; Caporalini, C; Conti, V; Diomedi-Camassei, F; Donofrio, V; Genitori, L; Gessi, M; Giangaspero, F; Gianno, F; Giordano, F; Guerrini, R; Migliastro, I; Moscardi, S; Mussa, F; Rossi, S; Santi, M; Sardi, I; Scagnet, M, 2021) |
| "Glioma is a lethal malignant brain cancer, and many reports have shown that abnormalities in the behavior of water and ion channels play an important role in regulating tumor proliferation, migration, apoptosis, and differentiation." | ( Cao, Y; Lee, I; Meng, X; Sun, J; Wang, W; Yang, R; Zhang, W, 2021) |
| "Glioma is the most general primary and lethal intracranial malignant tumor." | ( Chen, Y; Ding, Y; Gao, H; Huang, H; Lai, J; Liu, Z; Nie, W; Wang, Q; Xu, W; Zhang, C, 2021) |
| "Glioma is the predominant brain tumor with high death rate." | ( Darmonto, W; Dega, NK; Doong, RA; Ganganboina, AB; Tran, HL, 2021) |
| "Glioma is a prevalent primary tumor of the brain and spinal cord." | ( Aschner, M; Dadgostar, E; Fallah, M; Heidari-Soureshjani, R; Izadfar, F; Mirzaei, H; Tamtaji, OR, 2021) |
| "Glioma is a common type of malignant and aggressive tumor in the brain." | ( Chen, M; Feng, W; Li, J; Li, M; Li, T; Liu, Y; Xia, X; Yang, W; Yuan, Q; Zhang, S; Zhou, X; Zuo, M, 2022) |
| "Glioma is one of the most lethal and complex tumors, and thus, an effective drug delivery system must selectively target the tumor sites and release its cargos in a controlled manner." | ( Guo, L; Hai, L; Li, R; Lu, J; Peng, Y; Wu, Y; Zhao, Y, 2021) |
| "Malignant gliomas are a type of central nervous system cancer with extremely high mortality rates in humans." | ( Chang, SF; Cheng, CY; Luo, SJ; Wang, TC; Yang, WH, 2021) |
| "Glioma is the most common malignancy in the brain, with poor survival and often highly resistant to chemotherapy and radiotherapy." | ( Cui, B; Gao, K; Qiao, Y; Wang, T, 2021) |
| "Glioma is a common primary intracranial tumor, with high infiltration and aggression." | ( Chen, H; Tian, C; Zhang, L; Zheng, D, 2021) |
| "Gliomas are the most frequent type of brain tumor, with glioblastoma being the most common and malignant type." | ( Balcerzak, Ł; Bryszewska, M; Chrysostomou, V; Demetzos, C; Dimas, K; Garofalo, S; Ionov, M; Kajdanek, J; Kędzierska, M; Limatola, C; Miłowska, K; Naziris, N; Pippa, N; Pispas, S; Sereti, E, 2021) |
| "Gliomas are the most common and fatal brain tumors worldwide." | ( Bian, E; Huai, T; Huo, X; Li, Z; Wang, H; Xu, Y; Zhao, B, 2022) |
| "Gliomas are aggressive brain tumors with very high resistance to chemotherapy throughout the overexpression of multiple intracellular survival pathways." | ( A, M; A, Z; E, L; I, W; J, JG; J, SW; W, R, 2021) |
| "Glioma is the most common malignant tumor of the brain in adult patients." | ( Huang, R; Sun, S; Tong, X; Wang, K; Wang, Z; Wu, C, 2021) |
| "While high-grade gliomas are often resistant to therapy and associated with a poor outcome, children with low-grade gliomas face a better prognosis." | ( Anderson, J; Cantilena, S; de Boer, J; Hargrave, D; Meier, S; Michod, D; Niklison Chirou, MV; Salomoni, P, 2021) |
| "High-grade gliomas are notorious for a high recurrence rate even after curative resection surgery." | ( Chan, KC; Chou, WH; Lin, CP; Sung, CH; Tsuang, FY; Wu, CY, 2021) |
| "Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor." | ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021) |
| "Glioma is the most common primary malignant brain tumor with a dreadful overall survival and high mortality." | ( Chen, LQ; Duan, HX; Gao, ZG; Han, Y; Huang, W; Jin, MJ; Liu, W; Qi, LL; Wang, QM; Xin, X; Zhang, XT; Zhang, YY; Zhang, ZA, 2021) |
| "Glioma is the most frequent and aggressive adult brain tumor with maximum mortality." | ( Guo, H; He, J; Li, L; Wang, J; Wang, M; Wang, Y; Zhang, H, 2021) |
| "Glioma is a common intracranial tumor originated from neuroglia cell." | ( Gu, J; Ji, S; Liu, G; Rauniyar, S; Wang, Y; Ye, C; Zhan, W, 2021) |
| "Gliomas are a type of malignant central nervous system tumor with poor prognosis." | ( Cao, H; Cheng, Q; Dai, Z; Liu, Y; Liu, Z; Mo, Y; Wang, Z; Ye, W; Zhang, H; Zhang, X, 2021) |
| "Gliomas are the most common central nervous system tumors." | ( Bebyn, MG; Furtak, J; Kowalewski, J; Lewandowska, MA; Śledzińska, P, 2021) |
| "Gliomas are the most common primary malignant tumor in adults' central nervous system." | ( Chen, Q; Geng, R; Liu, B; Sun, Q; Xu, Y; Yuan, F; Zhang, H, 2021) |
| "Gliomas are primary brain tumors with still poor prognosis for the patients despite a combination of cytoreduction via surgery followed by a radio-chemotherapy." | ( Ackermann, A; Buchfelder, M; Çapcı, A; Savaskan, N; Tsogoeva, SB, 2021) |
| "Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis." | ( Chen, H; Gu, J; Jiang, J; Li, C; Li, Y; Luo, C; Qian, J; Wan, Z; Wang, J; Zhu, J, 2021) |
| "Gliomas are the most common malignant brain tumors in adults, characterized by a high proliferation and invasion." | ( Morrone, FB; Rockenbach, L; Scheffel, TB; Vargas, P, 2021) |
| "Glioma is the most common primary intracranial tumor." | ( Huang, L; Jiang, T; Li, G; Liu, Y; Zhao, Z; Zhou, K, 2021) |
| "Glioma is a type of malignant intracranial tumor." | ( Dong, X; Guo, W; Pi, Q; Tian, H; Yuemaierabola, A, 2021) |
| "Glioma is one of the most common types of primary intracranial tumors." | ( Li, C; Li, J; Li, L; Liu, W; Ma, W; Tang, Z; Zhang, X, 2021) |
| "Gliomas are the most frequent type of brain tumors, with a high mortality rate and a lack of efficient targeted therapy." | ( Chang, J; Wang, L; Xu, W; Yuan, J; Zhou, X, 2022) |
| "Glioma is the most common brain tumor and the main cause of death from primary brain tumors." | ( Jiang, Y; Li, Y; Song, Y; Su, X; Sun, Y; Wang, M; Wang, Y; Yu, P; Zhao, L, 2022) |
| "Infiltrative gliomas are the most common neoplasms arising in the brain, and remain largely incurable despite decades of research." | ( Drumm, M; Horbinski, C; Javier, R; McCortney, K; Sarkaria, JN; Wang, W, 2022) |
| "Gliomas are the most common brain tumors." | ( Aschner, M; Barati, E; Mirzaei, H; Razavi, ZS; Razzaghi, N; Tamtaji, OR, 2022) |
| "The incidence of gliomas is increasing." | ( Ding, P; Lu, B; Nie, X; Qian, Y; Xu, J, 2022) |
| "Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing." | ( Dohmen, H; Gött, H; Kiez, S; Kolodziej, M; Stein, M, 2022) |
| "Glioma is the most frequent primary cerebral tumor in adults." | ( Dilimulati, Y; Fu, Q; Kugeluke, Y; Li, S; Shaya, M; Zhou, Q, 2022) |
| "Gliomas are the most common brain malignancies characterized by high degree of aggressiveness and high mortality." | ( Gao, Y; Wang, G; Xi, G; Xie, T; Xu, T; Yang, L; Yang, Z; Zhang, X, 2022) |
| "Glioma is the most common and malignant brain tumor with poor prognosis." | ( Li, X; Luo, C; Nie, C; Qian, K; Wang, X; Zeng, Y, 2022) |
| "Glioma is one of the most common malignancies." | ( Bi, C; Ge, J; Lan, S; Liu, J; Liu, Z; Luo, X, 2022) |
| "Glioblastoma or glioma is the most common malignant brain tumor." | ( Argüelles, S; Ayala, A; Coveñas, R; Medina, R; Muñoz, M; Muñoz, MF; Rosso, M, 2022) |
| "Gliomas are primary brain tumors that account for ~80% of all malignant brain tumors." | ( Koltai, H; Peeri, H, 2022) |
| "Gliomas are the most common primary brain tumors in adults." | ( Blot, L; Chen, W; Courant, F; Decoville, M; Gosset, D; Hervouet-Coste, N; Maravat, M; Morisset-Lopez, S; Sarou-Kanian, V, 2022) |
| "Glioma is one of the main causes of cancer-related mortality worldwide and is associated with high heterogeneity." | ( Gao, X; Guo, Z; Xie, Q; Yang, Q; Zhang, J; Zhong, C, 2022) |
| "Gliomas are characterized by an inherent diffuse and irregular morphology that prevents defining a boundary between tumor and healthy tissue, both in imaging assessment and surgical field." | ( Bosque, JJ; García Vicente, AM; Pérez-Beteta, J; Pérez-García, VM; Soriano Castrejón, ÁM, 2022) |
| "Oligodendroglioma is a glioma subtype characterized by 1p/19q co-deletion and IDH1/IDH2 mutations, which predict a good prognosis, responsiveness to therapy, and an improved overall survival compared to other adult gliomas." | ( Adams, E; Eshleman, JR; Gocke, CD; Haley, L; Hardy, M; Huang, J; Long, P; Morsberger, L; Pallavajjala, A; Pallavajjala, R; Rodriguez, FJ; Stinnett, V; Zou, YS, 2022) |
| "Glioma is a common tumor that originated from the brain, and molecular targeted therapy is one of the important treatment modalities of glioma." | ( Gong, M; Jin, K; Li, L; Sun, C; Wang, Z; Wu, B; Xia, L; Zhang, S; Zou, Y, 2022) |
| "Glioma is one of the most common primary brain tumors." | ( Chang, L; Chang, Y; Dong, L; Guo, K; Li, N; Liang, S; Shi, Y; Wang, F; Wang, L; Wang, Y; Wei, X; Wu, H; Yan, F; Yin, Y, 2022) |
| "Gliomas are the most common primary brain tumors." | ( Alavi, A; Ayubcha, C; Borja, AJ; Nagaraj, C; Raynor, WY; Revheim, ME; Saini, J; Werner, TJ, 2022) |
| "Glioma is one of the most malignant brain tumors and diseases." | ( Chen, Z; Yan, Z; Zhang, M; Zhang, W, 2023) |
| "Glioma is the most lethal brain tumor with a poor prognosis, and a combination of multiple therapeutic strategies is critical for postoperative glioma treatment." | ( Cao, X; Chen, W; He, W; Li, S; Lu, H; Lv, L; Lv, W; Min, Z; Sun, S; Teng, C; Wang, X; Xin, H; Ye, L; Yin, H; Zhang, Q, 2022) |
| "Gliomas are the most common and malignant primary tumors of the central nervous system (CNS)." | ( Beylerli, O; Chen, X; Gareev, I; Liang, Y; Lu, E; Sufianov, A; Sun, J; Yang, G; Yuan, C; Zhao, S, 2022) |
| "Glioma is a tumor in the brain and spinal cord originating in the glial cells that surround the nerve cells." | ( He, Q; Li, M; Li, Z; Wan, X; Yang, H; Yang, X; Zhang, W, 2023) |
| "Glioma is the most common malignant tumor in the central nervous system and has a high mortality rate." | ( Guo, L; Wu, Z, 2022) |
| "Gliomas are common and aggressive brain tumors that carry a poor prognosis." | ( Ahmadi, SS; Bahrami, A; Ferns, GA; Mohamadian, M, 2022) |
| "Glioma is a common brain tumor with high mortality." | ( Chang, C; Dong, L; Guo, S; Wang, P; Wang, T; Xu, Z, 2022) |
| "Gliomas are a primary types of intracranial malignancies and are characterized by a poor prognosis due to aggressive recurrence profiles." | ( Du, J; Li, S; Peng, C; Peng, F; Xie, X, 2022) |
| "Glioma is the most common tumor in the central nervous system, which is often accompanied by poor prognosis." | ( Hu, D; Huang, G; Shen, C; Zhao, H, 2022) |
| "Gliomas are the most common primary intracranial tumors and closely related to circadian clock." | ( Chai, R; Huang, W; Li, N; Liang, Y; Liao, M; Ou, L; Tang, Q; Wang, S; Wang, X; Zheng, K, 2022) |
| "Glioma is the foremost recurrent type of brain tumor in humans; in particular, glioblastoma (GBM) is the main form of brain tumor (GBM) that is highly proliferative and impervious to apoptosis." | ( Ganesan, S; Jiang, B; Li, W; Su, Z; Wu, A; Yang, Z; Yuan, Z, 2022) |
| "Gliomas are the deadliest of all primary brain tumors, and they constitute a serious global health problem." | ( Abrahantes-Pérez, MDC; Barajas-Olmos, F; García-Ortiz, H; Hernández-Cuenca, YE; Jiménez-Morales, JM; Orozco, L; Quiñones-Hinojosa, A; Reyes-Abrahantes, A; Reyes-González, J; Ruiz-García, H, 2022) |
| "Glioma is one of the most common intracranial malignant tumors worldwide." | ( Qu, X; Xu, S; Xu, W; Yang, G; Zhang, K, 2022) |
| "Gliomas are the most common type of primary brain tumors, with high recurrence rate and mortality." | ( Fu, J; Peng, J; Tu, G, 2022) |
| "Glioma is a clinically heterogeneous disease with a poor prognosis." | ( Cao, J; Chen, Y; Gao, H; Huang, H; Lai, J; Li, C; Liu, Z; Sun, Y; Zhan, Z; Zhang, C, 2022) |
| "Gliomas are malignant tumors in the central nervous system." | ( Chen, B; Li, J; Meng, M; Yang, L; Zhang, L; Zhou, H; Zhou, X, 2022) |
| "Gliomas are highly aggressive cancer types that are in urgent need of novel drugs and targeted therapies." | ( Dowdy, T; Larion, M; Zaibaq, F, 2022) |
| "Gliomas are a heterogeneous group of brain tumours with high malignancy, for which surgical resection remains the mainstay of treatment at present." | ( Chen, J; Fan, W; Fu, Z; Wu, X; Xu, Y; Yang, J, 2023) |
| "Gliomas are incurable brain cancers with poor prognosis, with epigenetic dysregulation being a distinctive feature." | ( Burgess, ER; Crake, RLI; Dachs, GU; Das, AB; Magon, NJ; Morrin, HR; Phillips, E; Robinson, BA; Royds, JA; Slatter, TL; Vissers, MCM; Wiggins, GAR, 2022) |
| "Gliomas are the most common primary central nervous system tumors; despite recent advances in diagnosis and treatment, glioma patients generally have a poor prognosis." | ( Bebyn, M; Furtak, J; Koper, A; Koper, K; Śledzińska, P, 2023) |
| "Glioma is characterized by high mortality and low postoperative survival." | ( Li, Y; Ma, Q; Su, P; Wei, M; Wu, H; Xu, Y; Zhai, X; Zhang, H, 2022) |
| "Gliomas are the most common central cancer with high aggressive-capacity and poor prognosis, remaining to be the threat of most patients." | ( Jiang, J; Wang, S; Xu, Z, 2023) |
| "Glioma is one of the most frequent brain tumors with substantial mortality and morbidity, thus designing a simple sensor for achieving highly efficient determination of glioma cell is of great importance." | ( Lin, G; Lin, H; Lin, R; Shen, Z; Wang, W; Zheng, S, 2022) |
| "Gliomas are tumors of the primary central nervous system associated with poor prognosis and high mortality." | ( Du, J; Fan, H; Kuang, X; Peng, F; Xie, X, 2022) |
| "Glioma is the most common primary intracranial malignant tumor in the brain." | ( Gao, M; Gong, H; Hu, Z; Lin, Y; Liu, J, 2022) |
| "Glioma is characterized by highly invasive, progressive, and lethal features." | ( Chen, X; Dai, X; Dong, J; Gao, P; Guo, Q; Wang, X; Xiao, L; Yin, M; Zang, D; Zha, Z, 2022) |
| "Glioma is the most common of all central nervous system (CNS) malignancies and is associated with a poor prognosis." | ( Hua, Z; Li, C; Li, L; Wu, L; Yin, X, 2022) |
| "Glioma is a major brain tumor, and the associated mortality rate is very high." | ( Ahmed, SP; Ali, A; Arif, SH; Chosdol, K; Farheen, S; Hoda, MF; Kausar, T; Mariyath P M, M; Nayeem, SM; Shahi, MH, 2023) |
| "Glioma is the fast-growing, aggressive, and prevalent brain cancer with a great level of morbidity and mortality." | ( Ciftci, H; Sever, B, 2023) |
| "Gliomas are highly complex and heterogeneous tumors, rendering prognosis prediction challenging." | ( Feng, R; Fu, M; He, CK; Peng, X; Ren, Z; Tian, J; Wang, P; Wu, B; Zhang, M; Zhao, Q; Zhu, M, 2022) |
| "Glioma is the most common primary craniocerebral malignant tumor, arising from the canceration of glial cells in the brain and spinal cord." | ( Chen, Y; Liu, J; Pan, T; Qu, P; Wang, L; Wang, S; Wang, Y; Wu, Y; Xin, H; Yu, J, 2022) |
| "High-grade glioma is the most common malignant primary brain tumor in adults." | ( Garcia, C; Hayden-Gephart, M; Jain, S; Kim, L; Li, G; Rodrigues, A; Zhang, M, 2022) |
| "Gliomas are a group of primary intracranial tumors with high morbidity and mortality." | ( Cai, X; Feng, F; Heng, X; Ma, X; Zhao, Z, 2023) |
| "Glioma is a highly invasive primary brain tumour, making it challenging to accurately predict prognosis for glioma patients." | ( Chen, J; Li, J; Li, Y; Sun, Y; Wang, L; Wang, Y; Wang, Z, 2022) |
| "Glioma is one of the most commonly occurring malignant brain cancers with high recurrence and mortality." | ( Chen, J; Hou, JF; Kang, X, 2022) |
| "Gliomas are the most commonly occurring brain tumour in adults and there remains no cure for these tumours with treatment strategies being based on tumour grade." | ( Higgins, GS; McGowan, DR; Plaha, P; Roach, JR, 2022) |
| "Gliomas are the most commonly occurring brain tumour in adults and there remains no cure for these tumours with treatment strategies being based on tumour grade." | ( Higgins, GS; McGowan, DR; Plaha, P; Roach, JR, 2022) |
| "Gliomas are the most commonly occurring brain tumour in adults and there remains no cure for these tumours with treatment strategies being based on tumour grade." | ( Higgins, GS; McGowan, DR; Plaha, P; Roach, JR, 2022) |
| "Glioma is a deadly form of brain cancer, and the difficulty of treating glioma is exacerbated by the chemotherapeutic resistance developed in the tumor cells over the time of treatment." | ( Chung, S; Huang, J; Sugimoto, Y; Zhang, M, 2023) |
| "Glioma is a deadly form of brain cancer, and the difficulty of treating glioma is exacerbated by the chemotherapeutic resistance developed in the tumor cells over the time of treatment." | ( Chung, S; Huang, J; Sugimoto, Y; Zhang, M, 2023) |
| "Gliomas are immune system suppressive tumors, and the role of vitamin D is pivotal in the immune system." | ( Chaudary, MA; Shahid, S, 2022) |
| "Gliomas are immune system suppressive tumors, and the role of vitamin D is pivotal in the immune system." | ( Chaudary, MA; Shahid, S, 2022) |
| "Glioma is aggressive malignant tumor with limited therapeutic interventions." | ( Babu, PP; Chedupaka, R; Kuchana, V; Manga, V; Mudiraj, A; Ranjan, N; Vedula, RR; Venkatesham, P, 2023) |
| "Glioma is aggressive malignant tumor with limited therapeutic interventions." | ( Babu, PP; Chedupaka, R; Kuchana, V; Manga, V; Mudiraj, A; Ranjan, N; Vedula, RR; Venkatesham, P, 2023) |
| "Gliomas are diffuse intra-axial lesions, which can be accessed by multiple surgical corridors for a same location depending on the surgeon's preference." | ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Gliomas are diffuse intra-axial lesions, which can be accessed by multiple surgical corridors for a same location depending on the surgeon's preference." | ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| "Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis." | ( Hong, X; Ouyang, J; Peng, X; Wang, P; Xiao, B; Zhang, J; Zou, J, 2023) |
| "Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis." | ( Hong, X; Ouyang, J; Peng, X; Wang, P; Xiao, B; Zhang, J; Zou, J, 2023) |
| "Glioma is a fatal tumor originating from the brain, which accounts for most intracranial malignancies." | ( Fang, C; Liu, Y; Lou, M; Shao, A; Wang, W; Wang, X; Xu, H; Xu, Y; Yuan, L; Zhang, A; Zhang, Z; Zhu, Q, 2022) |
| "Glioma is the most common and aggressive primary brain tumor in adults with high morbidity and mortality." | ( Bi, S; Chen, H; Di, Z; Feng, L; Huang, X; Ma, Y; Shen, Y; Xu, W; Xue, M; Yu, Y; Zhu, T, 2023) |
| "Glioma is a common type of brain tumor with high incidence and mortality rates." | ( Cai, J; Chen, Q; Hong, Y; Sun, Q; Tian, D; Tong, S; Xu, Y; Ye, L; Ye, Z, 2023) |
| "Glioma is the most common primary tumor in the brain." | ( Hu, X; Liu, H; Liu, L; Luo, T; Wang, J; Zhang, C; Zhen, Z; Zheng, Y, 2022) |
| "Glioma is an extremely aggressive primary brain tumor, which is highly resistant to chemotherapy, presenting a therapeutic challenge." | ( Ding, L; Huo, M; Su, J; Yao, Q; Yin, W, 2023) |
| "Glioma is difficult-to-treat because of its infiltrative nature and the presence of the blood-brain barrier." | ( Das, CK; Das, S; Dhara, D; Kulkarni, G; Kundu, M; Mandal, M, 2023) |
| "Glioma is the most common malignant tumor of the central nervous system." | ( Chen, Y; Liu, Q; Ran, J; Wang, K; Wei, L; Zhao, Y; Zhu, S, 2023) |
| "High-grade gliomas are the most common intracranial malignancies, and their current prognosis remains poor despite standard aggressive therapy." | ( Chen, J; Dong, M; Liu, R; Luo, H; Ou, Y; Wang, D; Wang, X; Wang, Y; Yang, K; Zhang, Q, 2023) |
| "Gliomas are highly refractory intracranial cancers characterized by genetic and transcriptional heterogeneity." | ( Chen, J; Lei, B; Leng, W; Li, L; Li, S; Zhang, H; Zhao, H, 2023) |
| "Glioma is primary brain tumour with a poor prognosis." | ( Liu, L; Liu, X; Ruan, X; Wang, D; Wang, P; Xue, Y; Zhang, M, 2023) |
| "Canine glioma is one of the most common brain tumors with poor prognosis, making effective chemotherapy highly desirable." | ( Noguchi, S; Yasumura, M, 2023) |
| "Gliomas are the most common primary tumors in the central nervous system with poor prognosis." | ( Liu, DZ; Xu, SY, 2023) |
| "Glioma is the most common tumor of the central nervous system (CNS)." | ( Chen, Y; Guo, G; Jin, J; Li, R; Li, ZA; Zheng, J, 2023) |
| "Gliomas are considered one of the most malignant tumors in the body." | ( Ait Ssi, S; Badou, A; Ghouzlani, A; Kandoussi, S; Lakhdar, A; Naji, O; Rafii, S, 2023) |
| "Gliomas are the most aggressive type of malignant brain tumors." | ( Chen, M; Chen, Y; Jiang, X; Jin, Z; Li, Y; Liu, B; Pu, J; Shi, Y; Yan, D; Yang, C; Yuan, Y; Zhai, H; Zhang, C; Zhang, Y, 2023) |
| "Gliomas are aggressive brain tumors characterized by uncontrolled cell proliferation." | ( Fang, X; Feng, Y; Fu, M; Hua, W; Mao, Y; Wen, W; Zhang, J; Zhang, L, 2023) |
| "Gliomas are the most common intracranial nervous system tumours that are highly malignant and aggressive, and mitochondria are an important marker of metabolic reprogramming of tumour cells, the prognosis of which cannot be accurately predicted by current histopathology." | ( Cai, S; Cai, Y; Chai, Y; Fang, G; Lei, Y; Li, M; Mei, Z; Qin, C; Shen, L; Wu, J; Xiong, N; Xu, D; Yang, Z; Zhou, J, 2023) |
| "Malignant gliomas are known to be one of the most difficult diseases to diagnose and treat because of the infiltrative growth pattern, rapid progression, and poor prognosis." | ( Cui, X; Kang, C; Wang, Q; Wang, Y; Zhou, J, 2023) |
| "Glioma is one of primary brain tumours which has the worst clinical prognoses of patients." | ( Chen, B; Lin, F; Ou, S; Shi, S; Wang, W; Yu, Y, 2023) |
| "Gliomas are the most common primary intracranial malignant tumors." | ( Han, R; Hu, L; Li, M; Lin, N; Liu, H; Liu, X; Wang, X; Yang, W, 2023) |
| "Glioma is a fatal primary brain tumor." | ( Cheng, Q; Hu, Z; Liang, X; Liu, Z; Meng, M; Nie, J; Peng, R; Wang, Z; Wen, J; Yang, L; Zhang, L; Zhou, H, 2023) |
| "Glioma is a life-threatening malignancy where conventional therapies are ineffective." | ( Chen, J; He, Y; Huang, JD; Ji, J; Ke, Y; Li, T; Ma, C; Sun, H; Zeng, M; Zhong, J; Zhou, N, 2023) |
| "Glioma is the most common brain tumor and its treatment options are limited." | ( Chen, G; Jin, X; Luo, Y; Ou, J; Tan, W; Yang, X; Ye, L, 2023) |
| "Glioma is the most common primary malignant brain tumour, and survival is poor." | ( Li, H; Li, Q; Ma, Y; Wu, S; Yuan, Z; Zhang, J; Zhao, F, 2023) |
| "Diffuse gliomas are tumors that arise from glial or glial progenitor cells." | ( Ferrer, VP; Machado, GC, 2023) |
| "Glioma is the most common malignant brain tumor, and its behavior is closely related to the presence of glioma stem cells (GSCs)." | ( Chen, G; Deng, Z; Feng, M; Li, X; Wang, H; Zhao, G; Zhou, Y, 2023) |
| "Diffuse gliomas are a heterogeneous category of primary central nervous system tumors." | ( Baird, L; Beadling, C; Corless, C; Harrington, CA; Moore, S; Neff, T; Wood, MD, 2023) |
| "Glioma is the most common primary malignant tumor of the nervous system that starts in the glial cells." | ( Peng, W; Qi, X; Qian, Y, 2023) |
| "Gliomas are the most prevalent primary tumor in the central nervous system, with an abysmal 5-year survival rate and alarming mortality." | ( Liang, Q; Liu, Y; Xu, Z; Yan, Y, 2023) |
| "Malignant glioma is a highly vascularized tumor." | ( Liang, C; Niu, C; Wei, T; Zhang, T, 2023) |
| "Glioma is the most common primary central nervous tumor and its malignant and high recurrence rate are seriously threatening patient's life." | ( Li, C; Liang, J; Lu, J; Tan, Q; Yang, C; Zhang, Z; Zhou, Y, 2023) |
| "Gliomas are the most common primary central nervous system tumors, of which the malignant gliomas account for 60%-75%." | ( Bagul, SD; Basu, S; Chandak, AR; Shelly, D; Singh, BK; Singh, RK; Soni, BK; Sudhan, MD; Verma, P, 2023) |
| "Glioma is a common intracranial tumor and is generally associated with poor prognosis." | ( Li, J; Liang, C; Liu, Q; Liu, Y; Xiao, Z; Yan, X; Zhang, Y, 2023) |
| "Glioma is the most prevalent brain tumor, presenting with limited treatment options, while patients with malignant glioma and glioblastoma (GBM) have poor prognoses." | ( Guan, Z; Han, W; Hu, Y; Li, B; Peng, X; Qin, Y; Qiu, B; Qu, J; Sui, T; Wang, Z; Wu, F; Zhang, Y, 2023) |
| "Brain gliomas are difficult in the field of tumor therapy because of their high recurrence rate, high mortality rate, and low selectivity of therapeutic agents." | ( Chen, X; Jiang, W; Li, S; Sun, S; Wang, H; Xia, F; Xia, L, 2023) |
| "Low-grade gliomas are primary brain tumors that arise from glial cells and are usually treated with temozolomide (TMZ) as a chemotherapeutic option." | ( Ayala-Hernández, LE; Bosque, JJ; Chulián, S; Delobel, T; García-Ferrer, M; Murek, M; Pérez-Beteta, J; Pérez-García, VM; Piñero, P; Schucht, P, 2023) |
| "Glioma is a highly aggressive form of brain cancer characterized by limited treatment options and poor patient prognosis." | ( Chen, J; Li, J; Li, W; Long, Y; Wu, K; Xiang, C, 2023) |
| Excerpt | Reference |
|---|
| "Chronic in vitro treatment of C6 glioma cells with idazoxan did not significantly affect cholera or pertussis toxin catalyzed ribosylation of Gs and Gi/Go in these cells." | ( Bitran, JA; Chen, G; Gusovsky, F; Manji, HK; Potter, WZ, 1992) |
| "In vitro treatment of glioma cells with vincristine induced coordinate over-expression of both mdr1 and mdr3 genes associated with very high P-glycoprotein-mediated multidrug transport, resistant to the inhibitory activity of chemosensitizers like verapamil." | ( Meyermann, R; Schluesener, HJ, 1991) |
| "Alkali treatment of the glioma cell membranes prior to fusion inhibited most of the low Km GTPase activity and prevented the reconstitution of agonist binding." | ( Medzihradsky, F; Remmers, AE, 1991) |
| "Although treatment of rat gliomas with ACNU administered at 2 hrs prior to X-irradiation was most effective, it resulted in only the additive effect of the independent action of the two agents." | ( Katakura, R; Mashiyama, S; Sasaki, T; Suzuki, J; Takahashi, K; Yoshimoto, T, 1991) |
| "Agonist treatment of C6-glioma cells induces two altered states in beta-adrenergic receptors, a low affinity for the hydrophilic antagonist CGP-12177 and a low affinity for agonists like isoproterenol." | ( Hertel, C; Portenier, M; Staehelin, M, 1986) |
| "Lead-treated rat glioma (C6) and cerebellar astrocytes exhibited cytoplasmic extensions and the presence of glial endfeet after a 3-day exposure to 10(-6) to 10(-4) M PbCl2." | ( Cookman, GR; Hemmens, SE; Keane, GJ; King, WB; Regan, CM, 1988) |
| "Possible consequences for the treatment of human gliomas are shortly discussed." | ( Dingeldein, E; Jansen, J; Mandel, T; Mennel, HD; Rama, B, 1987) |
| "C-6 cells were more sensitive to this treatment than RSV glioma cells." | ( Hondo, H, 1988) |
| "Prolonged treatment of glioma cells with DMSO generated a more adherent, normal human fibroblastoid phenotype that grew with contact inhibition." | ( Brennan, RW; Geder, L; Kreider, JW; Ladda, RL; Page, RB; Rapp, F; Towfighi, J, 1987) |
| "Conclusively it was suggested that the treatment of glioma with peritumoural LDA on CT must be extended to the adjacent and distant part from the centre of the enhanced tumour element in the peritumoural LDA as well as the treatment of the enhanced tumour mass on CT in the poor and failed groups." | ( Maki, Y; Matsuki, T; Narushima, A; Tosa, J; Yoshii, Y, 1986) |
| "Antibody treatment of glioma cells in vitro caused evident cell surface alterations and pronounced growth depression of most cells." | ( Bise, K; Keiditsch, E; Mehraein, P; Mellert, U; Mellert, W; Stavrou, D, 1986) |
| "Isoprenaline treatment of C6-glioma cells induced a fast decrease in the number of beta-adrenergic receptors as determined by binding of [3H]CGP-12177, which paralleled the decrease in the hormonally stimulated adenylate cyclase activity." | ( Hertel, C; Müller, P; Portenier, M; Staehelin, M, 1983) |
| "Urine and plasma from untreated or glioma-bearing mice after injection of 111In-BLMC were analyzed by TLC and gel electrophoresis." | ( Farkas, RJ; Hoch, H; Hou, DY; Johnston, GS; Jones, AE; Miller, EE; Tsou, KC, 1984) |
| "Exponentially growing, hydrocortisone-treated glioma cell cultures when subjected to colchicine treatment accumulated mitoses for 16." | ( Armelin, HA; Farias, SE, 1982) |
| "Enzyme immunoassay of treated 36B10 glioma supernatant fluid for 8-isoprostane (a known oxidative metabolite) demonstrated a 10-fold increase of 8-isoprostane over 24 hours (123." | ( Cornelius, AS; Ryken, TC; Traynelis, VC, 1995) |
| "BCNU treatment of both glioma cell lines led to reduced nicotinamide adenine dinucleotide levels, indicating activation of PARP." | ( Berger, NA; Desnoyers, S; Malapetsa, A; Noë, AJ; Panasci, LC; Poirier, GG, 1996) |
| "We show that cRA-treated C6 glioma at 25 mg/kg/day for 18 days exhibits in vivo an increase T-PA activity, which is responsible for a localized tumor fibrinolytic activity." | ( Amalfitano, G; Berger, F; Kolodié, L; Le Magueresse, B; Pernod, G; Polack, B, 1996) |
| "We measured rCBF in 11 patients with untreated anaplastic gliomas or glioblastomas that were World Health Organization Grade III or IV restricted to one hemisphere with significant peritumoral edema who were receiving a standard dose of dexamethasone." | ( Behrens, PF; Ostertag, CB; Warnke, PC, 1998) |
| "Steroid therapy may be an effective treatment for gliomatosis cerebri before the terminal stage." | ( Hayashi, T; Hirose, Y; Murakami, H; Sagoh, M, 1998) |
| "Gene therapy for treatment of glioma often involves delivery of herpes simplex virus-1 thymidine kinase gene." | ( Hickey, WF; Kielian, T, 1999) |
| "Following 24 hours treatment of C6-glioma cells to varying doses of ethanol, the concentration of PCr and ATP decreased." | ( Geraminejad, P; Haghighat, N; McCandless, DW, 1999) |
| "A novel therapeutic approach to treat malignant gliomas with tachykinin NK1 receptor antagonists is suggested by these findings." | ( Bigioni, M; Irrissuto, C; Maggi, CA; Manzini, S; Nardelli, F; Palma, C, 2000) |
| "Depending on the cell line, treatment of glioma cells with temozolomide and X-rays can have either an additional effect or potentiate cell killing." | ( Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J, 2000) |
| "In the retrovirus group, all treated gliomas showed progression by MRI at the 3-month time point, whereas three of the seven patients treated with Adv/tk remained stable (p < 0." | ( Hurskainen, H; Immonen, A; Johansson, R; Kossila, M; Lehtolainen, P; Loimas, S; Paljärvi, L; Puranen, M; Puranen, P; Sandmair, AM; Turunen, M; Tyynelä, K; Vanninen, R; Vapalahti, M; Ylä-Herttuala, S, 2000) |
| "Like etoposide-induced cell death, treatment of glioma cells with the O2-*-releasing agent, pyrogallol, induced typical apoptosis and ceramide generation even in the presence of catalase." | ( Banno, Y; Kiyono, T; Nakagawa, M; Nakashima, S; Nishimura, Y; Nozawa, Y; Sakai, N; Sawada, M; Shinoda, J; Yamada, J; Yamakawa, H, 2001) |
| "The initial treatment of these gliomas includes surgery and IV chemotherapy." | ( Doolittle, ND; Jones, G; Lacy, C; Neuwelt, EA; Nickolson, HS; Osztie, E; Várallyay, P, 2001) |
| "Peroxynitrite treatment of human glioma cell lysates similarly resulted in selective tyrosine nitration of p53 and was also associated with loss of p53 DNA binding ability." | ( Cobbs, CS; Gillespie, GY; Harkins, LE; MacMillan-Crow, LA; Merrick, BA; Samanta, M, 2001) |
| "In the treated grade III glioma patients median disease-free interval was 56 months (range=15-60) and survival cannot be calculated as only two, within this group, died." | ( Bartolomei, M; Caliceti, P; Chinol, M; De Cicco, C; Fiorenza, M; Gatti, M; Grana, C; Mazzetta, C; Paganelli, G; Robertson, C, 2002) |
| "After this pretreatment period, glioma cells and DCs were mixed, and the interaction between DCs and apoptotic 9L tumor cells was assessed using two-color flow cytometry." | ( Chambers, WH; Erff, ML; Okada, H; Pollack, IF; Witham, TF, 2002) |
| "Taken together, treatment of glioma cells with PPARgamma agonists may hold therapeutic potential for the treatment of gliomas." | ( Feinstein, D; Grommes, C; Heneka, MT; Klockgether, T; Koenigsknecht, J; Kraus, JA; Landreth, G; Schlegel, U; Zander, T, 2002) |
| "Moreover, conditioned media from PTEN-treated glioma cells significantly diminished the ability of endothelial cells to grow and migrate." | ( Conrad, CA; Fueyo, J; Glass, TL; Gomez-Manzano, C; Hu, M; Jasti, SL; Jiang, H; Lee, HY; Liu, JL; Liu, TJ; Yung, WK, 2003) |
| "Procarbazine (PCB) has been used for treating gliomas for many years and here both agents were combined in the treatment." | ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "Accordingly, pretreatment of the glioma cells with Gleevec resulted in an enhancement in their radiosensitivity." | ( Brady, K; Burgan, WE; Camphausen, K; Cerra, MA; Oswald, KA; Russell, JS; Tofilon, PJ, 2003) |
| "CCNU was used to treat human glioma cell line BT-325 with different concentration of cytokines or NO donors, NO levels was measured by Griess assay and cell survival was evaluated by MTT assay." | ( Chen, ZL; Gao, RL, 2003) |
| "Expression of CD31 in resveratrol-treated gliomas was followed immunohistochemically to study the effect of resveratrol on the glioma-induced angiogenesis." | ( Chen, CK; Chen, JC; Chen, Y; Huang, HY; Lin, PY; Lin, SM; Su, YH; Tseng, SH, 2004) |
| "In this study, we treated C6-glioma cells with thapsigargin for 48 h." | ( Kuo, TC; Lin-Shiau, SY, 2004) |
| "SB-431542 treatment of glioma cultures inhibited proliferation, TGF-beta-mediated morphologic changes, and cellular motility." | ( Bigner, DD; Friedman, HS; Herbstreith, MH; Hjelmeland, AB; Hjelmeland, MD; Laping, NJ; Reese, ED; Rich, JN; Sathornsumetee, S; Wang, XF, 2004) |
| "Early treated V(+) gliomas reached similar volumes compared with V(-) gliomas." | ( Bendszus, M; Goldbrunner, RH; Kiderlen, M; Sasaki, M; Tonn, JC; Wood, J, 2004) |
| "Ten patients with untreated gliomas were examined on a 1." | ( Buslei, R; Fahlbusch, R; Ganslandt, O; Gruber, S; Moser, E; Nimsky, C; Stadlbauer, A, 2004) |
| "Long-term pre-treatment of C6-gliomas with venlafaxine followed by an acute challenge with isoproterenol (a beta-adrenoceptor agonist), resulted in increased p90Rsk phosphorylation (three-fold) versus control levels (isoproterenol alone)." | ( Khawaja, XZ; Liang, JJ; Storm, S, 2004) |
| "We have observed that treatment of human glioma cells with morphine in the nanomolar range of concentration affects the mitochondrial membrane potential." | ( Arcuri, E; Arese, M; Bacchi, A; Cardelli, P; Citro, G; Mastronicola, D; Mercadante, S; Sarti, P, 2004) |
| "Here we show that treatment of rat C6 glioma cells with the raft disruptor methyl-beta-cyclodextrin (MCD) doubles the binding efficiency (i." | ( Bari, M; Battista, N; Fezza, F; Finazzi-Agrò, A; Maccarrone, M, 2005) |
| "Chemo-therapeutic treatment of glioma patients has minor success." | ( Golubnitschaja, O; Haertel, N; Moenkemann, H; Schüller, H; Trog, D, 2005) |
| "A previous study showed that treatment of C6 glioma cells with 10 mM ammonium chloride monia") for 24 h decreases taurine uptake and evokes sodium-dependent taurine efflux, indicating reversal of the taurine transporter (TauT)-mediated transport as an underlying mechanism." | ( Albrecht, J; Dybel, A; Zabłocka, B; Zielińska, M, 2005) |
| "In addition, treatment of glioma C6-positive rats with Cas IIgly reduced tumor volume and mitotic and cell proliferation indexes, and increased apoptotic index." | ( Bravo-Gómez, ME; Cruz, A; Gracia-Mora, I; Luvia, ST; Marquez-Rosado, L; Moreno-García, ME; Osorio-Rico, L; Palencia, G; Rodríguez-Enriquez, S; Rodríguez-Ropon, A; Ruiz-Ramírez, L; Sánchez, A; Sotelo, J; Trejo-Solís, C; Zúñiga, S, 2005) |
| "However, it is difficult to treat malignant glioma with p53 gene therapy alone because of problems with resistance or a less-than-satisfactory response to the treatment." | ( Aoki, H; Endo, S; Kanzawa, T; Komata, T; Kon, T; Kondo, S; Nashimoto, T; Takahashi, H; Tanaka, R; Uzuka, T, 2005) |
| "Cyclical dosing of KM-233 to treat U87 glioma in a SCID mouse xenograft side pocket model was effective at reducing the tumor burden with both systemic and intratumoral administration." | ( Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006) |
| "In the follow-up of treated gliomas, CT and MRI can often not differentiate radionecrosis from recurrent tumor." | ( Blond, S; Dubois, F; Le Jeune, FP; Steinling, M, 2006) |
| "While cells from untreated gliomas often have over-representation of chromosome 7, chromosome 22 is typically under-represented." | ( Hank, NC; Scheck, AC; Shapiro, JR, 2006) |
| "One hundred and eighteen patients treated for glioma were retrospectively included in this study." | ( Bauchet, L; Chevalier, J; Comte, F; Coubes, P; Fabbro, M; Hauet, JR; Mariano-Goulart, D; Rigau, V; Rossi, M; Zanca, M, 2006) |
| "A new method for treating malignant glioma by concurrent intra-arterial injection of adriamycin during thermotherapy was performed in seven patients with malignant glioma, four males and three females, with five cases of glioblastoma and two of anaplastic oligodendroglioma." | ( Takahashi, H; Tanaka, R; Uzuka, T, 2006) |
| "We demonstrate that noscapine treatment of human glioma U87MG and T98G cell lines exposed to the hypoxic mimetic agent, CoCl2, inhibits hypoxia-mediated HIF-1alpha expression and transcriptional activity as measured by decreased secretion of VEGF, a HIF-1 target gene." | ( Ali, MA; Lan, L; Lukyanov, Y; Newcomb, EW; Schnee, T; Zagzag, D, 2006) |
| "Finally, treatment of glioma cell lines with prostaglandin E2, the predominant product of COX-2 activity, results in increased vascular endothelial growth factor expression, thus potentially linking elevations in COX-2 expression with tumor angiogenesis in malignant gliomas." | ( Shu, HK; Xu, K, 2007) |
| "We also found that As(2)O(3) treatment of glioma cells significantly up-regulated DR5, a death receptor of TRAIL." | ( Choi, KS; Kim, EH; Kim, SU; Kwon, TK; Sohn, S; Yoon, MJ, 2008) |
| "The role of chemotherapy in the treatment of gliomas is no longer limited to recurrent disease." | ( Weller, M, 2008) |
| "Upon co-treatment of glioma cells with As2O3 and berberine, cancer cell metastasis can be significantly inhibited, most likely by blocking the PKC-mediated signaling pathway involved in cancer cell migration." | ( Chou, FP; Kuo, HC; Lin, TH; Lu, FJ, 2008) |
| "The siRNA-treated glioma cell lines GOS-3 and U87-MG were subjected to two chemotherapeutic agents; taxol and Temozolomide (TMZ)." | ( Patel, R; Shervington, A, 2008) |
| "Expression of CD31 in tetrandrine-treated gliomas was followed to study its effect on glioma-induced angiogenesis." | ( Chen, JC; Chen, Y; Tseng, SH, 2009) |
| "Combination treatment of glioma cells with dasatinib and temozolomide resulted in a significant increase in cell cycle disruption and autophagic cell death." | ( de Groot, J; LaFortune, T; Milano, V; Piao, Y, 2009) |
| "Temozolomide, the standard treatment of gliomas, although not an ABCG2 substrate, increases the SP in glioma cells, especially in cells missing PTEN." | ( Bleau, AM; Brennan, CW; Fomchenko, EI; Hambardzumyan, D; Holland, EC; Huse, JT; Ozawa, T, 2009) |
| "Pathological analyses showed that the treated gliomas presented a significant reduction in the mitotic index and other histological characteristics that indicate a less invasive/proliferative tumor." | ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| "In 17alpha-AED treated T98G glioma cells there was an increase in the autophagy related proteins Atg5 and beclin-1." | ( Dent, P; Graf, MR; Jia, W; Johnson, RS; Loria, RM; Mitchell, C, 2009) |
| "The results displayed that treatment of C6 glioma cells with SDT resulted in the occurrence of apoptosis, which was associated with the production of ROS and loss of MMP." | ( Dai, S; Hu, S; Wu, C, 2009) |
| "NVP-BEZ235 treatment of glioma cell lines led to G(1) cell cycle arrest and induced autophagy." | ( Garcia-Echevrria, C; Koul, D; LaFortune, T; Liu, TJ; Maira, SM; Shen, RJ; Tiao, N; Yung, WK, 2009) |
| "The present study demonstrates that treatment of glioma cells with clinically achievable doses of gemcitabine results in acid sphingomyelinase activation, lysosomal accumulation of ceramide, cathepsin D activation, Bax insertion into the mitochondria, and cell death." | ( Dumitru, CA; Gulbins, E; Sandalcioglu, IE; Wagner, M; Weller, M, 2009) |
| "Combined treatment of glioma cells with sulfasalazine and celastrol led to chemosensitization, as suggested by increased celastrol-induced cell cycle arrest, apoptosis, and down-regulation of the Hsp90 client protein, epidermal growth factor receptor." | ( Alvarado, O; Blower, PE; Gout, PW; Huang, Y; Pham, AN; Ravula, R, 2010) |
| "Concurrent treatment of the glioma cell line U87-MG with siRNA 1 and temozolomide (TMZ) resulted in a 13-fold reduction in the dose of TMZ required to achieve a similar effect if TMZ was used alone." | ( Cruickshanks, N; Munje, C; Patel, R; Shervington, A; Shervington, L; Thakkar, D, 2010) |
| "In contrast, in the uPARAP siRNA-treated glioma cells, polymeric actin became organized in stress fibers and the lamellipodia disappeared, characteristic of immobile cells." | ( Hamada, K; Kawase, T; Ohta, S; Takahashi, S; Toda, M; Yamada-Okabe, H; Yoshida, K, 2011) |
| "To elucidate the mechanism of TAM treatment on gliomas, we hypothesised that PI3K/Akt and MAPK signaling pathway may play important roles on TAM-induced apoptosis in C6 glioma cells." | ( Ding, Y; Feng, Y; Huang, J; Shen, X; Xie, F, 2010) |
| "Addition of chlorotoxin to siRNA-treated glioma cells only slightly increased the suppression of invasion." | ( Hung, KN; Leung, GK; Lui, VC; Lung, SS; Pu, JK, 2010) |
| "In vitro, caffeine treatment reduced glioma cell proliferation through G(0)/G(1)-phase cell cycle arrest by suppressing Rb phosphorylation." | ( Cho, GJ; Cho, YW; Choi, J; Choi, WS; Jeong, JY; Kang, SS; Kim, HJ; Kim, JS; Ku, BM; Lee, YK; Roh, GS; Ryu, J, 2011) |
| "VPA is also used in the treatment of glioma-associated seizures with or without intracranial operation." | ( Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT, 2011) |
| "The long-term TMZ-treated astroglioma cells, but not the Hs683 oligodendroglioma cells, developed in vivo a certain level of resistance to TMZ, which correlated with the up- regulation of CXCL2, CXCL3 and CXCL8 expression in the U373 and T98G astroglioma cells." | ( Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S, 2011) |
| "PGE2-treated astroglioma cells showed a marked upregulation of IL-8, C/EBP-β, and CHOP, as well as increased proliferation and decreased apoptosis compared with untreated cells." | ( Alafaci, C; Caffo, M; Caruso, G; Salpietro, FM; Teti, D; Tomasello, F; Venza, M; Visalli, M, 2011) |
| "Moreover, treatment of glioma stem-like cells with Eckol significantly attenuated anchorage-independent growth on soft agar and tumor formation in xenograft mice." | ( An, S; Hyun, JW; Hyun, KH; Kim, MJ; Kim, RK; Lee, SJ; Lim, EJ; Park, MJ; Suh, Y; Yoon, CH, 2011) |
| "We examined 42 patients with pretreated gliomas (29 patients) or brain metastases (13 patients) prospectively by FET- and MET-PET on the same day." | ( Astner, ST; Grosu, AL; Heinemann, F; Molls, M; Nieder, C; Riedel, E; Schwaiger, M; Weber, WA; Wester, HJ; Wiedenmann, N, 2011) |
| "Gliomas contain a small number of treatment-resistant glioma stem cells (GSCs), and it is thought that tumor regrowth originates from GSCs, thus rendering GSCs an attractive target for novel treatment approaches." | ( Christofk, H; Dekmezian, C; Della Donna, L; Evers, P; Lagadec, C; Masui, K; Matsutani, T; Mischel, PS; Pajonk, F; Popescu, R; Poulou, M; Reue, K; Vergnes, L; Vlashi, E, 2011) |
| "In the quest of a curative radiotherapy treatment for gliomas, new delivery modes are being explored." | ( Deman, P; Martinez-Rovira, I; Prezado, Y; Thengumpallil, S, 2011) |
| "The lack of effective treatments for gliomas makes them a significant health problem and highlights the need for the development of novel and innovative treatment approaches." | ( Dam, MA; Eskin, A; Kim, W; Konkankit, VV; Koya, RC; Liau, LM; Nelson, S; Prins, RM; Ribas, A, 2011) |
| "Interestingly, decitabine treatment of T98 glioma cells also sensitized them to Fas-dependent apoptosis with an agonistic antibody, while a Fas blocking antibody could largely prevent the enhanced functional recognition by NY-ESO-1 specific T cells." | ( Dam, MA; Eskin, A; Kim, W; Konkankit, VV; Koya, RC; Liau, LM; Nelson, S; Prins, RM; Ribas, A, 2011) |
| "Progress in treating diffuse gliomas remains limited and is principally concerned with the confirmation that cystostatics as nitrosureum derivatives and temozolomide play a role in the treatment of these tumours." | ( van den Bent, MJ, 2011) |
| "Here we explored the use of folate to treat gliomas in a mouse model, using tumours induced by either PDGF-B or Ras/Akt overexpression, or by ethylnitrosourea (ENU) treatment." | ( Campone, M; Cartron, PF; Debien, E; Hervouet, E; Loussouarn, D; Martin, SA; Menanteau, J; Olivier, C; Pouliquen, D; Vallette, FM, 2012) |
| "We reviewed our experience treating high-grade gliomas of the spinal cord with standard intracranial regimens including temozolomide and bevacizumab." | ( Gavrilovic, IT; Kaley, TJ; Mondesire-Crump, I, 2012) |
| "Radiotherapy is a standard treatment for glioma patient with or without surgery; radiosensitizer can increase tumor sensitivity for radiotherapy." | ( Cao, G; Cen, Y; Ding, G; Jiang, W; Li, B; Li, X; Liu, D; Liu, X; Pang, X; Sun, J; Yan, W; Zheng, J; Zhou, H; Zhou, W, 2012) |
| "Shikonin treated C6 glioma cells presented electron-lucent cytoplasm, loss of plasma membrane integrity and intact nuclear membrane in morphology." | ( Fan, W; Ge, P; Huang, C; Luo, Y; Yang, F; Zhao, H; Zhao, J, 2013) |
| "A currently studied experimental treatment for gliomas consists of intratumoral injection of oncolytic viruses (OV), such as oncolytic herpes simplex virus type 1 (oHSV)." | ( Chiocca, EA; Haseley, A; Kaur, B; Meisen, H; Okemoto, K; Wagner, B, 2013) |
| "Also, calcitriol pretreated glioma cells exhibited increased cell death following ALA-based photodynamic therapy." | ( Chen, X; Fu, C; Guan, H; Li, X; Liu, H; Liu, Y; Liu, Z; Teng, L; Wang, C; Wang, L; Yang, G; Yin, F; Zhang, D; Zhang, Y; Zhao, B; Zhao, S, 2014) |
| "This finding suggests that the combined treatment of glioma cells with calcitriol plus ALA may provide an effective and selective therapeutic modality to enhance ALA-induced PpIX fluorescent quality for improving discrimination of tumor tissue and PDT efficacy." | ( Chen, X; Fu, C; Guan, H; Li, X; Liu, H; Liu, Y; Liu, Z; Teng, L; Wang, C; Wang, L; Yang, G; Yin, F; Zhang, D; Zhang, Y; Zhao, B; Zhao, S, 2014) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "In vitro pretreatments of F98 glioma and B16 melanoma cells with l-DOPA, followed by exposure to BPA increased boron uptake, as determined by inductively coupled plasma-optical emission spectroscopy (ICP-OES)." | ( Barth, RF; Chandra, S; Haider, SA; Huo, T; Kabalka, GW; Shaikh, AL; Yang, W, 2014) |
| "Furthermore, U0126 treatment in glioma cells induced an initial inhibition of ERK1/2 phosphorylation, followed by up-regulated ERK1/2 phosphorylation concomitant with diminished surface expression of PDGFRA." | ( Chen, D; Englund, E; Fan, X; Liu, M; Luan, C; Na, M; Persson, A; Ran, L; Renström, E; Salford, LG; Sun, Y; Zhang, E; Zuo, D, 2014) |
| "Furthermore, we treated two glioma cell lines with a demethylating agent (5-aza-2'-deoxycitidine, 5-aza-dC) or a remethylating agent (folate) to alter the methylation status of PDGF-B." | ( Dong, C; Jin, G; Liu, F; Mi, R; Zhang, J; Zhou, Y, 2014) |
| "The current treatments for gliomas are mainly based on surgery, chemotherapy, and radiotherapy, which exhibit limited efficacy." | ( Chen, K; Chen, X; Gan, D; Ke, Y; Li, Y; Peng, Y; Xu, D, 2014) |
| "Therapeutic outcome for the treatment of glioma was often limited due to low permeability of delivery systems across the blood-brain barrier (BBB) and poor penetration into the tumor tissue." | ( Cai, W; Chen, J; Gao, F; Gao, H; He, Q; Mei, L; Shi, K; Wang, Y; Zhu, P; Zong, T, 2014) |
| "First, we treated glioma cell lines and primary astrocytes with various isoflavonoids and phytoestrogens." | ( Buchfelder, M; Doerfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Hore, N; Savaskan, NE; Schwarz, M; Sehm, T; Weiss, R, 2014) |
| "However, the optimal regimen for treating high-grade glioma cannot be concluded without more clinical trials." | ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| "We hypothesized that co-treatment of glioma with a BH3-mimetic and HDACI may induce cellular death." | ( Foster, KA; Jane, EP; Morales, A; Pollack, IF; Premkumar, DR, 2014) |
| "In the posttreatment glioma group, high thalamic SUVs and high thalamocortical SUV ratios were associated with short survival in Cox regression analysis." | ( Barger, GR; Chakraborty, PK; Juhász, C; Kamson, DO; Lee, TJ; Mittal, S; Muzik, O; Robinette, NL; Snyder, M; Varadarajan, K, 2014) |
| "Therefore, HDACi treatment causes glioma cell entry into mitosis before DNA damage could be repaired and to the formation of an aberrant mitotic spindle that results in glioma cell death through mitotic catastrophe-induced apoptosis." | ( Blasco-Angulo, N; Comella, JX; Cornago, M; Garcia-Alberich, C; Herreros, J; Llovera, M; Nager, M; Sanchis, D; Vall-Llaura, N, 2014) |
| "These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway." | ( Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S, 2015) |
| "72 patients with treated cerebral glioma investigated by PET-Met were identified from prospective database." | ( Brodskaya, ZL; Gurchin, AF; Skvortsova, TY, 2014) |
| "The follow-up of treated low-grade glioma (LGG) requires the evaluation of subtle clinical changes and MRI results." | ( Chamorro Santos, CE; Gómez-Río, M; Lardelli-Claret, P; Llamas-Elvira, JM; Luque Caro, R; Olivares Granados, G; Rodríguez-Fernández, A; Santiago Chinchilla, A; Testart Dardel, N; Zurita Herrera, M, 2015) |
| "Toward this goal, the authors treated different glioma cell lines with quinine (QN), quinacrine (QNX), mefloquine (MFQ), and hydroxychloroquine (HCQ) and investigated endoplasmic reticulum (ER) stress-induced cell death, autophagy, and cell death." | ( Chen, TC; Cho, HY; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH, 2015) |
| "Temozolomide is used widely to treat malignant glioma, but the overall response to this agent is generally poor." | ( Balyasnikova, IV; Bernal, GM; Cahill, KE; Crawley, CD; Larsen, GF; Mansour, NM; Nunez, L; Spretz, R; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W, 2015) |
| "This makes SR141716 treated-glioma cells potent targets for allogeneic NK cell-mediated recognition through a NKG2D restricted mechanism, thus priming them for NK cell antitumor reactivity." | ( Bifulco, M; Catapano, G; Ciaglia, E; D'Alessandro, A; Fiore, D; Gazzerro, P; Laezza, C; Malfitano, AM; Pagano Zottola, AC; Picardi, P; Pisanti, S; Proto, MC; Torelli, G, 2015) |
| "In this study, we have treated neuroglioma cells expressing the double Swedish mutation of human amyloid precursor protein (H4APPsw) with several glycosphingolipid (GSL)-modulating agents, and we have analyzed the impact of the aberrant ganglioside composition on the GSK3 activation state." | ( Barrier, L; Ingrand, S; Noel, A, 2015) |
| "Despite advances in the development of treatment methods, glioma remains among the cancer types with a high rate of mortality." | ( Cui, Y; He, L; Yang, F, 2015) |
| "According to different treatments, glioma U251 cells were randomly divided into blank group, Lipofectamine group, siRNA-Gli1 group, BCNU group and combination group." | ( Bai, J; Dong, X; Guo, W; Tian, H; Yang, X, 2015) |
| "Notably, co-treatment of C6 glioma cells with 400 µmol/l NaHS and AOAA (an inhibitor of CBS) largely suppressed the above NaHS-induced effects." | ( Chen, J; Feng, J; Guo, R; He, J; Liu, C; Lu, Y; Zhang, W; Zhang, Y; Zhen, Y, 2015) |
| "Sodium-MR imaging data of patients with treatment-naïve glioma WHO grades I-IV (n = 34; mean age, 51." | ( Badde, S; Bendszus, M; Benkhedah, N; Biller, A; Hertenstein, A; Kleesiek, J; Nagel, A; Neumann, JO; Sahm, F; Wick, W, 2016) |
| "Herein, we demonstrate that treatment of C6 glioma cells with CAPE and Dasatinib significantly decrease the activity of catalase [CAT]." | ( Balkhi, HM; Gul, T; Haq, E, 2016) |
| "At 48-h treatment, the glioma cells maintained 60% viability in the presence of celecoxib or LLW-3-6 at the maximum concentration tested (40 μM)." | ( Winfield, LL; Yerokun, T, 2015) |
| "CpG-1826 treatment of GL261 gliomas implanted in immune competent mice induced tumor growth delay associated with increased tumor recruitment of macrophages and B cells." | ( Jordan, M; Waxman, DJ, 2016) |
| "The study included 53 patients (29 treated for 29 gliomas and 24 treated for 26 brain metastases)." | ( Beal, K; Gavrilovic, I; Hatzoglou, V; Omuro, A; Peck, KK; Rubel, J; Schneider, T; Ulaner, G; Woo, KM; Yang, TJ; Young, RJ; Zhang, Z, 2016) |
| "In terms of the effective treatment of brain glioma, this study provides conclusive evidence of the successful development of the anti-cancer agent HCD conjugated with enteric-coated MSN as a delivery control mechanism with enhanced dissolution characteristics." | ( Lee, CH; Lin, SX; Thiyagarajan, V; Weng, CF, 2016) |
| "Current therapies for treating malignant glioma exhibit low therapeutic efficiency because of strong systemic side effects and poor transport across the blood brain barrier (BBB)." | ( Dong, H; Guo, Z; Jin, M; Liu, Z; Qiu, X; Xiong, H; Zhang, W, 2016) |
| "Annexin-V/PI staining showed that T11TS treatment in glioma-induced rats increases apoptosis of glioma-associated endothelial cells within glioma milieu compared to brain endothelial cells in glioma induced and control groups." | ( Bhattacharya, D; Chaudhuri, S; Datta, A; Singh, MK, 2017) |
| "These results revealed a promising treatment of glioma by oligodeoxynucleotide aptamer." | ( Chen, Y; Cheng, Y; Li, Y; Nigim, F; Song, Y; Yu, Z; Zhang, S; Zhao, G; Zhou, G, 2016) |
| "They might be employed to treat the glioma if both hepatic and renal injuries are prevented." | ( Gao, Y; Huang, KQ; Liu, JJ; Shi, S; Yang, XF; Yang, XH; Zhao, S; Zhao, ZJ; Zheng, HC, 2017) |
| "Thirty untreated glioma patients (27 high-grade) underwent simultaneous PET/MRI on a 3 T hybrid scanner obtaining structural and dynamic susceptibility contrast sequences." | ( Förster, S; Gempt, J; Göttler, J; Kaczmarz, S; Kluge, A; Lukas, M; Meyer, B; Mustafa, M; Preibisch, C; Pyka, T; Ringel, F; Schwaiger, M; Zimmer, C, 2017) |
| "The 24-hour treatment of glioma cells with several concentrations of Q (25, 50 and 100μM) did not cause any cytotoxic effects, while the administration of Q-derivatives, such as acylated and brominated quercetin, caused a sharp increase in cell death." | ( Dell'Albani, P; Di Marco, B; Foti, MC; Grasso, S; Rocco, C, 2017) |
| "A pretreatment of glioma cells with rottlerin before hypericin induced PDT led to significant increase in apoptosis accompanied by the decrease of intracellular oxidative stress and increase of phosphorylated Bcl-2 in the cytoplasm of U87 MG cells." | ( Horvath, D; Huntosova, V; Miskovsky, P; Misuth, M, 2017) |
| "The potential of canine cMSCs-PTX for treatment of canine gliomas should be investigated further." | ( Alessandri, G; Aralla, M; Bonomi, A; Brini, AT; Ceserani, V; Coccè, V; Ghezzi, E; Guercio, A; Parati, E; Pascucci, L; Pessina, A; Pettinari, L; Zeira, O, 2017) |
| "For the treatment of glioma and other central nervous system diseases, one of the biggest challenges is that most therapeutic drugs cannot be delivered to the brain tumor tissue due to the blood-brain barrier (BBB)." | ( Chen, J; Lei, D; Ren, P; Wang, B; Wang, G; Wang, W; Wang, Y; Yin, T; Yin, Y; Zou, D, 2017) |
| "The clinical treatment for glioma is very difficult due to its infiltration and specific growth locations." | ( Fu, F; Hua, H; Li, X; Li, Y; Liu, W; Shi, Y; Sun, K; Wang, A; Zhang, X, 2017) |
| "Uptake of the two tracers in untreated gliomas was similar." | ( de Paula Faria, D; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Langendijk, JA; Maas, B; Parente, A; Shoji, A; van Waarde, A; Zijlma, R, 2018) |
| "Therefore, treatment of glioma cells with dihydroartemisinin exhibited an antitumor effect by the induction of apoptosis." | ( Guo, CG; Li, DH; Liu, Y; Xiao, LM; Xu, CH; Zeng, EM; Zheng, SY, 2017) |
| "As a chemotherapy strategy for treating brain glioma, functional targeting daunorubicin liposomes have the potential to eliminate brain glioma along with glioma stem cells." | ( Ju, RJ; Liu, L; Lu, WL; Mu, LM; Xie, HJ; Yan, Y; Zeng, F; Zhang, CX; Zhao, WY; Zhao, Y, 2016) |
| "Posttherapy changes in treated glioma patients cannot be reliably differentiated from tumor recurrence." | ( Aheer, D; Arora, G; Biswas, A; Garg, A; Hazari, PP; Kumar, R; Mishra, AK; Sharma, A; Sharma, P, 2018) |
| "Forty-seven patients with treatment-naïve glioma received preoperative DCE-MRI before stereotactic biopsy." | ( Chen, H; Cheng, W; Chu, Z; Di, N; Jiang, X; Liu, X; Wang, B; Xie, Q; Zhou, J, 2019) |
| "Exendin-4 treatment inhibited glioma cell survival, proliferation, migration and invasion." | ( Chang, YH; Li, QY; Nie, ZJ; Zhang, YG; Zhang, YL, 2018) |
| "Nanoparticle treatment of glioma cells decreased the angiogenesis of human umbilical vein endothelial cells (HUVEC) cocultured with U87 (p53 wild type) and was not effective for U118 (p53 mutant) cells." | ( Chwalibog, A; Grodzik, M; Jaworski, S; Sawosz, E; Strojny, B; Wierzbicki, M, 2018) |
| "Moreover, treatment of human glioma stem cells (hGSCs) with Lck-I, results in significant inhibition of self-renewal and tumor-sphere formation." | ( Fajardo, E; Fiser, A; Moreno, MM; Ness, J; Sarkar, A; Snyder, KM; Tapinos, N; Toms, SA; Zepecki, JP, 2019) |
| "In the study, we treated C6 rat glioma cells with 25 mg/ml Dulcitol for 24 h." | ( Chen, B; Li, F; Wang, H; Xu, X; Zhang, T; Zhang, Y, 2020) |
| "Their long-term treatment in glioma cells caused the induction of physiological differentiation into astrocytes." | ( Afzal, S; Garg, S; Ishida, Y; Kaul, SC; Terao, K; Wadhwa, R, 2019) |
| "Celastrol-treated glioma cells exhibited decreased cell viability after the use of autophagy inhibitors." | ( Gao, W; Liu, X; Song, Y; Wang, L; Wang, X; Zhao, P; Zhu, Y, 2019) |
| "Forty-eight pretreated high-grade glioma patients with anatomical MRI findings suspicious for progression (median time elapsed since last treatment was 16 weeks) were investigated using DWI and dynamic FET PET." | ( Borggrefe, J; Ceccon, G; Fink, GR; Galldiks, N; Kabbasch, C; Langen, KJ; Lichtenstein, T; Lohmann, P; Shah, NJ; Stoffels, G; Werner, JM, 2019) |
| "We found the treatment of C6-glioma cells with LPS results in deleterious effects, including the augmentation of inflammatory cytokine levels (tumor necrosis factor-α, interleukin-1β), and suppresses the Akt phosphorylation." | ( Bo, J; Duan, L; Tao, F; Wu, J; Yao, K; Zhang, J; Zhu, J; Zu, H, 2020) |
| "Finally, cyclophosphamide-treated dying glioma cells producing type-I interferons were an effective vaccine against drug-naïve glioma cells implanted in vivo." | ( Du, B; Waxman, DJ, 2020) |
| "Paclitaxel shows little benefit in the treatment of glioma due to poor penetration across the blood-brain barrier (BBB)." | ( Arrieta, VA; Baran, A; Canney, M; Carpentier, A; Chen, L; Desseaux, C; Dmello, C; Gonzalez-Buendia, E; Horbinski, C; James, CD; Kane, JR; Magnusson, LP; Muzzio, M; Sonabend, AM; Stupp, R; Zhang, DY, 2020) |
| "We used selenium nanoparticles to treat commercial glioma cell lines, and patient-derived glioma cells, and then used the MTT assay to determine selenium nanoparticles effect against these." | ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B; Zhang, Q; Zhou, N, 2020) |
| "Effective treatment of glioma and other central nervous system (CNS) diseases is hindered by the presence of the blood-brain barrier (BBB)." | ( Du, R; McGinty, S; Pontrelli, G; Wang, G; Wang, J; Wang, Y; Yang, M; Yin, T; Yin, Y, 2020) |
| "The standard-of-care treatments for gliomas include surgical resection, radiation, and temozolomide administration; however, they have been ineffective in providing significant increases in median survival." | ( Aikins, M; Castro, MG; Hassani Najafabadi, A; Kadiyala, P; Lowenstein, PR; Moon, JJ; Scheetz, L; Schwendeman, A; Son, S; Sun, X, 2020) |
| "Sevoflurane (sev) was employed to treat glioma cells." | ( Kang, LY; Liu, WW; Tang, L; Wang, W; Wei, WT; Xia, R; Xu, W; Xue, R; Zheng, JW, 2020) |
| "There are no effective treatments for gliomas after progression on radiation, temozolomide, and bevacizumab." | ( Anker, CJ; Boucher, K; Burt, LM; Cohen, AL; Colman, H; Jensen, R; Johnson, B; Salzman, K; Shrieve, DC, 2020) |
| "However, the effects of NG treatment on glioma remain to be elucidated." | ( Chen, F; Dai, Z; Ma, Y; Song, T; Wang, Y; Wu, J; Zhang, M, 2020) |
| "Radiation is a current standard treatment of glioma." | ( Dong, H; Feng, B; Gao, C; Gao, X; Mao, W; Sun, C; Wang, J; Wang, Y; Yang, Y; Zhang, B; Zhang, H; Zhang, J; Zhang, L, 2020) |
| "Thus, treatment of glioma cells without ERN1 enzymatic activity by glucose deprivation condition lead to down-regulation of the expression level of ZEB2 and SPAG4 as well as to more significant up-regulation of PRRX1 and TGIF1 genes." | ( He, Q; Khita, OO; Lahanovska, YO; Liu, K; Minchenko, DO; Minchenko, OH; Rudnytska, OV; Tsymbal, DO; Viletska, YM, 2020) |
| "Taken together, we propose that pre-treatment of glioma cells with metformin sensitize tumor cells to CAP, which may serve as a potential therapeutic strategy for glioma." | ( Ahmad, N; Meng, X; Sun, M; Yang, F; Yang, J; Yu, H; Zhao, R; Zhou, Y; Zhu, C; Zhuang, J, 2021) |
| "Temozolomide (TMZ) has been used to treat glioma." | ( Jia, X; Li, W; Liu, Q; Ma, Q; Wang, X; Yan, P, 2021) |
| "In conclusion, bexarotene treatment in C6 glioma cells could modulate apoptosis profile, DNA damage, ROS production, and reduction of TAS levels through inhibition of NF-κB by enhancing PPARγ expression." | ( Hacioglu, C; Kacar, S; Kanbak, G; Kar, F; Sahinturk, V, 2021) |
| "This introduces new ideas for the treatment of gliomas." | ( Dai, X; Huang, B; Ni, S; Nyalali, AMK; Sun, J; Xu, F; Zhang, K; Zhao, H; Zhu, W, 2021) |
| "Current therapeutic options for the treatment of gliomas rely mainly on surgical resection and the inhibition of tumour cell proliferation by irradiation and chemotherapy." | ( Bernreuther, C; Glatzel, M; Hagel, C; Matschke, J; Rehfeld, M; Willenborg, K, 2021) |
| "As a mainstay in the current treatment of glioma at present, chemotherapeutic agents usually show inadequate therapeutic efficiency due to their low blood brain barrier traversal and brain targeting, together with tumor multidrug resistance." | ( Gao, Y; Ji, J; Liu, A; Qiu, N; Xi, Y; Xu, J; Yang, X; Zhai, G, 2021) |
| "Effective treatment of glioma requires a nanocarrier that can cross the blood-brain barrier (BBB) to target the tumor lesion." | ( Li, J; Tan, T; Wang, R; Wang, W; Xie, T; Yin, L; You, Y; Zeng, H; Zeng, Y; Zeng, Z, 2021) |
| "Effective treatment of glioma still stands as a challenge in medical science." | ( Barik, B; Kumar, LA; Pattnaik, G; Satapathy, BS, 2021) |
| "The effective treatment of glioma through conventional chemotherapy is proved to be a great challenge in clinics." | ( Farshbaf, M; Hemmati, S; Khosroushahi, AY; Mojarad-Jabali, S; Motasadizadeh, H; Valizadeh, H; Zarebkohan, A, 2022) |
| "To synergistically treat glioma with a combination chemotherapy, we design and prepare novel cascade-targeted liposomes (Lip-TPGS) using glucose and triphenylphosphonium (TPP) as targeting moieties, which could intelligently deliver redox-sensitive doxorubicin (DOX) prodrugs (SDOX) and chemotherapeutic sensitizer lonidamine (LND)." | ( Du, Y; Hai, L; Li, R; Lu, J; Peng, Y; Shi, Y; Wu, Y; Yang, Z; Zhao, Y; Zhao, Z, 2022) |
| "Macrophages primed with DOX-PCI treated glioma cells appeared to be highly effective as APCs and, when injected into host animals, could delay and, in some cases, prevent tumor development." | ( Berg, K; Christie, C; Hirschberg, H; Madsen, SJ; Nguyen, L; Peng, Q, 2022) |
| "After treatment of glioma with apigenin 20 mg/kg for 12 days, irradiation 8 Gray twice or their combination, the tumor volume and weight were decreased, especially in the combination group." | ( Fan, K; Huang, H; Jia, C; Xie, M; Xie, T; Zhao, Y, 2022) |
| "The current standard treatment for gliomas is surgical resection supplemented by postoperative chemotherapy." | ( Beylerli, O; Chen, X; Gareev, I; Liang, Y; Lu, E; Sufianov, A; Sun, J; Yang, G; Yuan, C; Zhao, S, 2022) |
| "Chemotherapy is a conventional treatment for glioma, but its efficacy is greatly limited due to low blood-brain barrier (BBB) permeability and lack of specificity." | ( Chen, J; Hai, L; Liu, Q; Lu, R; Wang, S; Wu, Y; Yang, C; Yang, Z, 2022) |
| "Oleanolic acid is a promising drug for treating gliomas, but its underlying mechanism is unclear." | ( Huang, J; Lin, S; Xu, L; Zhu, F, 2022) |
| "Moreover, the efficacy of the treatment of glioma cells with temozolomide (TMZ) and Gli1 inhibitor GANT61 was higher than that of TMZ alone." | ( Ahmed, SP; Ali, A; Arif, SH; Chosdol, K; Farheen, S; Hoda, MF; Kausar, T; Mariyath P M, M; Nayeem, SM; Shahi, MH, 2023) |
| "Notably, treating glioma cells with xanthatin resulted in obvious activation of the PI3K-Akt-mTOR signaling pathway, as indicated by increased mTOR and Akt phosphorylation, decreased ULK1 phosphorylation, which is important in modulating autophagy." | ( Bi, S; Chen, H; Di, Z; Feng, L; Huang, X; Ma, Y; Shen, Y; Xu, W; Xue, M; Yu, Y; Zhu, T, 2023) |
| "Next, we treated the glioma cells with Insulin, a stimulator of PI3K/AKT/mTOR signaling, to confirm that Magnolol induced autophagy by inhibiting this pathway." | ( Das, CK; Das, S; Dhara, D; Kulkarni, G; Kundu, M; Mandal, M, 2023) |
| "Despite advances in the diagnosis and treatment of gliomas, the median survival time after diagnosis of GBM remains low, approximately 15 months, with a 5-year overall survival rate of only 6." | ( Ferrer, VP; Machado, GC, 2023) |
| "However, its efficacy in the treatment of gliomas and the underlying mechanisms remain unclear." | ( Guo, S; Liu, X; Wang, C, 2023) |